Tina Cascone, M.D., Ph.D.

Peer-Reviewed Articles

1. Li H, Hong L, Rocha P, Bach R, Solis Soto LM, Rinsurongkawong W, Zhang B, Araujo HA, Elamin YY, Altan M, Arrechedera CA, Zhou J, Khan KB, Lu W, Young E, Gay CM, Cascone T, Byers LA, Skoulidis F, Blumenschein G, Fossella FV, Tsao A, Negrao MV, Vokes N, Wu J, Tran HT, Wistuba II, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Le X, Zhang J. MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung Cancer. Cancers (Basel) 17(23), 2025. e-Pub 2025. PMID: 41375002.
2. Peng F, Sinjab A, Dai Y, Treekitkarnmongkol W, Yang S, Gomez Bolanos LI, Zhou T, Chen M, Serrano AG, Krishna A, Karimi N, Sharma M, Basi A, Pei G, Liao J, Liu Y, Feng J, Rahal Z, Liu Y, Jiang J, Yu K, Noun T, Liu Y, Khan K, Cho KS, Chen J, Solis LM, Mazzilli S, Dubinett S, Cascone T, Spira AE, Swisher S, Jimbo N, Hayashi T, Kishikawa S, Takamochi K, Itoh T, Yao T, Suzuki K, Kalhor N, Wistuba II, Li M, Moghaddam SJ, Fujimoto J, Burks J, Myers J, Akdemir K, Wang L, Kadara H. Multimodal spatial-omics reveal co-evolution of alveolar progenitors and proinflammatory niches in progression of lung precursor lesions. Cancer Cell, 2025. e-Pub 2025. PMID: 41202811.
3. Salehjahromi M, Li H, Showkatian E, Saad MB, Qayati M, Ismail SM, Sujit SJ, Muneer A, Aminu M, Hong L, Han X, Heeke S, Cascone T, Le X, Vokes N, Gibbons DL, Toumazis I, Ostrin EJ, Antonoff MB, Vaporciyan AA, Jaffray D, Kay FU, Carter BW, Wu CC, Godoy MCB, Lee JJ, Gerber DE, Heymach JV, Zhang J, Wu J. Radiomics for Dynamic Lung Cancer Risk Prediction in USPSTF-Ineligible Patients. Cancers (Basel) 17(21), 2025. e-Pub 2025. PMID: 41228201.
4. Cascone T, Bonanno L, Guisier F, Insa A, Liberman M, Bylicki O, Livi L, Egenod T, Corre R, Kim DW, Garcia Campelo MR, Provencio Pulla M, Shim BY, Metro G, Bennouna J, Bielska AA, Yohannes AR, He Y, Dowson A, Kar G, McGrath L, Kumar R, Grenga I, Spicer J, Forde PM. Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial. Nat Med 31(8):2788-2796, 2025. e-Pub 2025. PMID: 40450142.
5. Saad MB, Al-Tashi Q, Hong L, Verma V, Li W, Boiarsky D, Li S, Petranovic M, Wu CC, Carter BW, Shroff GS, Cascone T, Le X, Elamin YY, Altan M, Heeke S, Sheshadri A, Chang JY, Lee PP, Liao Z, Gibbons DL, Vaporciyan AA, Lee JJ, Wistuba II, Haymaker C, Mirjalili S, Jaffray D, Gainor JF, Lou Y, Di Federico A, Pecci F, Awad M, Ricciuti B, Heymach JV, Vokes NI, Zhang J, Wu J. Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLC. Nat Commun 16(1):6828, 2025. e-Pub 2025. PMID: 40707438.
6. Rahal Z, El Darzi R, Moghaddam SJ, Cascone T, Kadara H. Tumour and microenvironment crosstalk in NSCLC progression and response to therapy. Nat Rev Clin Oncol 22(7):463-482, 2025. e-Pub 2025. PMID: 40379986.
7. Mitchell KG, Lee Y, Deboever N, Negrao MV, Tran HT, Parra E, Byers L, Reuben A, Federico L, Bernatchez C, Wang J, Antonoff MB, Vaporciyan AA, Swisher SG, Cascone T, Wistuba II, Heymach JV, Gibbons DL, Zhang J, McGrail DJ, Sepesi B, Haymaker CL. Intratumoral neutrophil-to-lymphocyte ratio is mirrored by circulating neutrophil-to-lymphocyte ratio in non-small cell lung cancer. J Immunother Cancer 13(6), 2025. e-Pub 2025. PMID: 40555561.
8. Awada G, Cascone T, van der Heijden MS, Blank CU, Kok M, Chalabi M. The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types. Nat Cancer 6(6):967-987, 2025. e-Pub 2025. PMID: 40555863.
9. Heeke S, Gandhi S, Tran HT, Lam VK, Byers LA, Gibbons DL, Gay CM, Altan M, Antonoff MB, Le X, Tu J, Saad MB, Pek M, Poh J, Ngeow KC, Tsao A, Cascone T, Negrao MV, Wu J, Blumenschein GR Jr, Heymach JV, Elamin YY. Longitudinal Tracking of ALK-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNA. JTO Clin Res Rep 6(4):100795, 2025. e-Pub 2025. PMID: 40160974.
10. Cascone T, William WN Jr. Perioperative nivolumab results in favourable long-term outcomes in patients with locally advanced resectable non-small-cell lung cancer. Nat Rev Clin Oncol, 2024. e-Pub 2024. PMID: 39627503.
11. Kim, ST, Chu, Y, Misoi, MW, Suarez-Almazor, M, Tayar, JH, Lu, H, Buni, M, Kramer, J, Rodriguez, E, Hussain, Z, Neelapu, SS, Wang, RJ, Shah, AY, Tannir, NM, Campbell, M, Gibbons, DL, Cascone, T, Lu, C, Blumenschein, GR, Altan, M, Lim, B, Valero, V, Loghin, ME, Tu, J, Westin, SN, Naing, A, Garcia-Manero, G, Hassan, NA, Tawbi, H, Hwu, P, Oliva, IC, Davies, MA, Patel, SP, Zou, J, Futreal, A, Diab, A, Wang, L, Nurieva, R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nature communications 15(1), 2024. e-Pub 2024. PMID: 38965214.
12. Sujit, S, Aminu, M, Karpinets, T, Chen, P, Saad, M, Salehjahromi, M, Boom, JD, Qayati, M, George, JM, Allen, H, Antonoff, MB, Hong, L, Hu, X, Heeke, S, Tran, HT, Le, X, Elamin, YY, Altan, M, Vokes, N, Sheshadri, A, Lin, J, Zhang, J, Lu, Y, Behrens, MC, Godoy, M, Wu, CC, Chang, JY, Chung, C, Jaffray, D, Wistuba, II, Lee, JJ, Vaporciyan, AA, Gibbons, DL, Heymach, J, Zhang, J, Cascone, T, Wu, J. Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights. Nature communications 15(1), 2024. e-Pub 2024. PMID: 38605064.
13. Spicer JD, Cascone T, Wynes MW, Kelly KL. Why and When Do We Invasively Restage After Neoadjuvant Chemoimmunotherapy?. J Thorac Oncol 19(12):e98-e99, 2024. e-Pub 2024. PMID: 39645317.
14. Xia Y, Wang K, Zhao J, Arter Z, Zhang Y, Zhou J, Lu Y, Zeng L, Du R, Owens JA, Elamin YY, Gay CM, Skoulidis F, Tsao AS, Lu C, Cascone T, Gibbons DL, Zhang J, Chen O, Mok KK, Nagasaka M, Li W, Heymach JV, Ignatius Ou SH, Li M, Le X. Receptor tyrosine kinase fusion-mediated resistance to EGFR-TKI in EGFR-mutant NSCLC: a multi-center analysis and literature review. J Thorac Oncol, 2024. e-Pub 2024. PMID: 39622411.
15. Zhou N, Leung CH, William WN Jr, Weissferdt A, Pataer A, Godoy MCB, Carter BW, Fossella FV, Tsao AS, Blumenschein GR, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Tran HT, Wu J, Solis Soto LM, Kadara H, Swisher SG, Vaporciyan AA, Gibbons DL, Lin HY, Lee JJ, Heymach JV, Negrao MV, Sepesi B, Cascone T. Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. J Immunother Cancer 12(10), 2024. e-Pub 2024. PMID: 39448200.
16. Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbo F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Lieghl N, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Janne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature, 2024. e-Pub 2024. PMID: 39385035.
17. Pan, K, Owens, J, Elamin, YY, Lu, C, Routbort, MJ, Zhang, J, Fossella, FV, Vailati Negrao, M, Altan, M, Pozadzides, JV, Skoulidis, F, Tsao, A, Cascone, T, Heymach, JV, Ostrin, EJ, Le, X. Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFR Germline Mutations. Journal of Thoracic Oncology 19(10):1438-1448, 2024. e-Pub 2024. PMID: 38866326.
18. Spicer JD, Cascone T, Wynes MW, Ahn MJ, Dacic S, Felip E, Forde PM, Higgins KA, Kris MG, Mitsudomi T, Provencio M, Senan S, Solomon BJ, Tsao MS, Tsuboi M, Wakelee HA, Wu YL, Chih-Hsin Yang J, Zhou C, Harpole DH, Kelly KL. Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer. J Thorac Oncol 19(10):1373-1414, 2024. e-Pub 2024. PMID: 38901648.
19. Rahal Z, Liu Y, Peng F, Yang S, Jamal MA, Sharma M, Moreno H, Damania AV, Wong MC, Ross MC, Sinjab A, Zhou T, Chen M, Tarifa Reischle I, Feng J, Chukwuocha C, Tang E, Abaya C, Lim JK, Leung CH, Lin HY, Deboever N, Lee JJ, Sepesi B, Gibbons DL, Wargo JA, Fujimoto J, Wang L, Petrosino JF, Ajami NJ, Jenq RR, Moghaddam SJ, Cascone T, Hoffman K, Kadara H. Inflammation mediated by gut microbiome alterations promotes lung cancer development and an immunosuppressed tumor microenvironment. Cancer Immunol Res, 2024. e-Pub 2024. PMID: 39269772.
20. Florez N, Patel SP, Wakelee H, Bazhenova L, Massarelli E, Salgia R, Stiles B, Peters S, Malhotra J, Gadgeel SM, Nieva JJ, Afkhami M, Hirsch FR, Gubens M, Cascone T, Levy B, Sabari J, Husain H, Ma PC, Backhus LM, Iyengar P, Lee P, Miller R, Sands J, Kim E. Proceedings of the 1st biannual bridging the gaps in lung cancer conference. Oncologist, 2024. e-Pub 2024. PMID: 39237103.
21. Cascone T, Spicer JD, Provencio Pulla M. Perioperative Nivolumab in Resectable Lung Cancer. Reply. N Engl J Med 391(6):573-574, 2024. e-Pub 2024. PMID: 39115074.
22. Hines, J, Cameron, RB, Esposito, A, Kim, L, Porcu, L, Nuccio, A, Viscardi, G, Ferrara, R, Veronesi, G, Forde, PM, Taube, JM, Vokes, EE, Bestvina, CM, Dolezal, JM, Sacco, M, Monteforte, M, Cascone, T, Garassino, MC, Torri, V. Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC. Journal of Thoracic Oncology 19(7):1108-1116, 2024. e-Pub 2024. PMID: 38461929.
23. Cascone, T, Awad, MM, Spicer, JD, He, J, Lu, S, Sepesi, B, Tanaka, F, Taube, JM, Cornelissen, R, Havel, L, Karaseva, N, Kuzdzal, J, Petruzelka, L, Wu, L, Pujol, JL, Ito, H, Ciuleanu, TE, de Oliveira Muniz Koch, L, Janssens, A, Alexandru, A, Bohnet, S, Moiseenko, F, Gao, Y, Watanabe, Y, Coronado Erdmann, C, Sathyanarayana, P, Meadows-Shropshire, S, Blum, SI, Provencio Pulla, M. Perioperative Nivolumab in Resectable Lung Cancer. New England Journal of Medicine 390(19):1756-1769, 2024. e-Pub 2024. PMID: 38749033.
24. Sorin, M, Prosty, C, Ghaleb, L, Nie, K, Katergi, K, Shahzad, MH, Dubé, LR, Atallah, A, Swaby, A, Dankner, M, Crump, T, Walsh, LA, Fiset, PO, Sepesi, B, Forde, PM, Cascone, T, Provencio, M, Spicer, JD. Neoadjuvant Chemoimmunotherapy for NSCLC. JAMA Oncology 10(5):621-633, 2024. e-Pub 2024. PMID: 38512301.
25. Corrigan, KL, Xu, T, Sasaki, Y, Lin, R, Chen, AB, Welsh, JW, Lin, SH, Chang, JY, Ning, MS, Gandhi, S, O'Reilly, MS, Gay, CM, Altan, M, Lu, C, Cascone, T, Koutroumpakis, E, Sheshadri, A, Zhang, X, Liao, L, Zhu, XR, Heymach, JV, Nguyen, Q, Liao, Z. Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma. Radiotherapy and Oncology 193, 2024. e-Pub 2024. PMID: 38311031.
26. Han, G, Sinjab, A, Rahal, Z, Lynch, AM, Treekitkarnmongkol, W, Liu, Y, Serrano, A, Feng, J, Liang, K, Khan, KB, Lu, W, Hernandez, S, Liu, Y, Cao, X, Dai, E, Pei, G, Hu, J, Abaya, C, Gomez Bolanos, L, Peng, F, Chen, M, Parra Cuentas, ER, Cascone, T, Sepesi, B, Moghaddam, SM, Scheet, PA, Vailati Negrao, M, Heymach, JV, Li, M, Dubinett, SM, Stevenson, CS, Spira, AE, Fujimoto, J, Solis Soto, LM, Wistuba, II, Chen, J, Wang, L, Kadara, HN. An atlas of epithelial cell states and plasticity in lung adenocarcinoma. Nature 627(8004):656-663, 2024. e-Pub 2024. PMID: 38418883.
27. Salehjahromi, M, Karpinets, T, Sujit, S, Qayati, M, Chen, P, Aminu, M, Saad, MB, Bandyopadhyay, R, Hong, L, Sheshadri, A, Lin, J, Antonoff, MB, Sepesi, B, Ostrin, EJ, Toumazis, I, Huang, P, Cheng, C, Cascone, T, Vokes, N, Behrens, C, Siewerdsen, JH, Hazle, JD, Chang, JY, Zhang, J, Lu, Y, Godoy, M, Chung, C, Jaffray, D, Wistuba, II, Lee, JJ, Vaporciyan, AA, Gibbons, DL, Gladish, G, Heymach, JV, Wu, CC, Zhang, J, Wu, J. Synthetic PET from CT improves diagnosis and prognosis for lung cancer. Cell Reports Medicine 5(3), 2024. e-Pub 2024. PMID: 38471502.
28. Khushalani, N, Ott, PA, Ferris, R, Cascone, T, Schadendorf, D, Le, DT, Sharma, MR, Barlesi, F, Sharfman, WH, Luke, JJ, Melero, I, Lathers, D, Neely, J, Suryawanshi, S, Sanyal, A, Holloway, JL, Suryawanshi, R, Ely, S, Segal, NH. Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors. Journal for immunotherapy of cancer 12(3), 2024. e-Pub 2024. PMID: 38458639.
29. Nuccio A, Viscardi G, Salomone F, Servetto A, Venanzi FM, Riva ST, Oresti S, Ogliari FR, Viganò M, Bulotta A, Cameron R, Esposito A, Hines J, Bianco R, Reni M, Cascone T, Garassino MC, Torri V, Veronesi G, Cinquini M, Ferrara R. Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies. Eur J Cancer 195:113404, 2023. e-Pub 2023. PMID: 37948842.
30. Sepesi B, Mehran R, Spicer J, Cascone T. NEOSTAR trial and the current status of neoadjuvant therapy in non-small cell lung cancer. J Thorac Cardiovasc Surg. e-Pub 2023. PMID: 37923289.
31. Tran HT, Heeke S, Sujit S, Vokes N, Zhang J, Aminu M, Lam VK, Vaporciyan A, Swisher SG, Godoy MCB, Cascone T, Sepesi B, Gibbons DL, Wu J, Heymach JV. Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small cell lung cancer. Ann Oncol. e-Pub 2023. PMID: 37992871.
32. Cascone T, Kar G, Spicer JD, García-Campelo R, Weder W, Daniel DB, Spigel DR, Hussein M, Mazieres J, Oliveira J, Yau EH, Spira AI, Anagnostou V, Mager R, Hamid O, Cheng LY, Zheng Y, Blando J, Tan TH, Surace M, Rodriguez-Canales J, Gopalakrishnan V, Sellman BR, Grenga I, Soo-Hoo Y, Kumar R, McGrath L, Forde PM. Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase 2 NeoCOAST Platform Trial. Cancer Discov 13(11):2394-2411, 2023. e-Pub 2023. PMID: 37707791.
33. Wang K, Du R, Myall NJ, Lewis WE, Uy N, Hong L, Skoulidis F, Byers LA, Tsao A, Cascone T, Pozadzides J, Tu J, Negrao MV, Gibbons DL, Park K, Rinsurongkawong W, Lee JJ, Gandara D, Behl D, Shu CA, Riess JW, Baik C, Wakelee HA, Vaporciyan AA, Heymach JV, Zhang J, Le X. BRIEF REPORT: Real-world efficacy and safety of amivantamab for EGFR-mutant non-small cell lung cancer (NSCLC). J Thorac Oncol. e-Pub 2023. PMID: 38012986.
34. Feldman H, Sepesi B, Leung CH, Lin H, Weissferdt A, Pataer A, William WN, Walsh GL, Rice DC, Roth JA, Mehran RJ, Hofstetter WL, Antonoff MB, Rajaram R, Gibbons DL, Lee JJ, Heymach JV, Vaporciyan AA, Swisher SG, Cascone T. Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. e-Pub 2023. PMID: 37816395.
35. Dacic S, Travis W, Redman M, Saqi A, Cooper WA, Borczuk A, Chung JH, Glass C, Lopez JM, Roden AC, Sholl L, Weissferdt A, Posadas J, Walker A, Zhu H, Wijeratne MT, Connolly C, Wynes M, Bota-Rabassedas N, Sanchez-Espiridion B, Lee JJ, Berezowska S, Chou TY, Kerr K, Nicholson A, Poleri C, Schalper KA, Tsao MS, Carbone DP, Ready N, Cascone T, Heymach J, Sepesi B, Shu C, Rizvi N, Sonett J, Altorki N, Provencio M, Bunn PA, Kris MG, Belani CP, Kelly K, Wistuba I, Committee IP. International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy. J Thorac Oncol 18(10):1290-1302, 2023. e-Pub 2023. PMID: 37702631.
36. Weissferdt A, Leung CH, Lin H, Sepesi B, William WN, Swisher SG, Cascone T, Lee JJ, Pataer A. Pathologic Processing of Lung Cancer Resection Specimens After Neoadjuvant Therapy. Mod Pathol 37(1):100353. e-Pub 2023. PMID: 37844869.
37. Chang JY, Lin SH, Dong W, Liao Z, Gandhi SJ, Gay CM, Zhang J, Chun SG, Elamin YY, Fossella FV, Blumenschein G, Cascone T, Le X, Pozadzides JV, Tsao A, Verma V, Welsh JW, Chen AB, Altan M, Mehran RJ, Vaporciyan AA, Swisher SG, Balter PA, Fujimoto J, Wistuba II, Feng L, Lee JJ, Heymach JV. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet 402(10405):871-881, 2023. e-Pub 2023. PMID: 37478883.
38. Garon EB, Spira AI, Goldberg SB, Chaft JE, Papadimitrakopoulou V, Cascone T, Antonia SJ, Brahmer JR, Camidge DR, Powderly JD, Wozniak AJ, Felip E, Wu S, Ascierto ML, Elgeioushi N, Awad MM. Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial. J Thorac Oncol 18(8):1094-1102, 2023. e-Pub 2023. PMID: 37146752.
39. Morgillo, F, D'Aiuto, E, Troiani, T, Martinelli, E, Cascone, T, De Palma, R, Orditura, M, De Vita, F, Ciardiello, F. Retraction notice to “Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors” [Lung Cancer 71 (2011) 283–290, (S0169500210002746), (10.1016/j.lungcan.2010.06.005)]. Lung Cancer 181, 2023. e-Pub 2023. PMID: 37167905.
40. Saad MB, Hong L, Aminu M, Vokes NI, Chen P, Salehjahromi M, Qin K, Sujit SJ, Lu X, Young E, Al-Tashi Q, Qureshi R, Wu CC, Carter BW, Lin SH, Lee PP, Gandhi S, Chang JY, Li R, Gensheimer MF, Wakelee HA, Neal JW, Lee HS, Cheng C, Velcheti V, Lou Y, Petranovic M, Rinsurongkawong W, Le X, Rinsurongkawong V, Spelman A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Antonoff MB, Sepesi B, Lewis J, Wistuba II, Hazle JD, Chung C, Jaffray D, Gibbons DL, Vaporciyan A, Lee JJ, Heymach JV, Zhang J, Wu J. Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study. Lancet Digit Health 5(7):e404-e420, 2023. e-Pub 2023. PMID: 37268451.
41. Altan M, Wang Y, Song J, Welsh J, Tang C, Guha-Thakurta N, Blumenschein GR, Carter BW, Wefel JS, Ghia AJ, Yeboa DN, McAleer MF, Chung C, Woodhouse KD, McGovern SL, Wang C, Kim BYS, Weinberg JS, Briere TM, Elamin YY, Le X, Cascone T, Negrao MV, Skoulidis F, Ferrarotto R, Heymach JV, Li J. Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial. J Immunother Cancer 11(7), 2023. e-Pub 2023. PMID: 37402581.
42. Patel SA, Nilsson MB, Yang Y, Le X, Tran HT, Elamin YY, Yu X, Zhang F, Poteete A, Ren X, Shen L, Wang J, Moghaddam SJ, Cascone T, Curran M, Gibbons DL, Heymach JV. IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC. Clin Cancer Res 29(7):1292-1304, 2023. e-Pub 2023. PMID: 36595561.
43. Li M, Liao K, Chen AJ, Cascone T, Shen Y, Lu Q, Shih YT. Disparity in checkpoint inhibitor utilization among commercially insured adult patients with metastatic lung cancer. J Natl Cancer Inst 115(3):295-302, 2023. e-Pub 2023. PMID: 36346180.
44. Cascone, T, Leung CH, Weissferdt A, Pataer A, Carter BW, Godoy MCB, Feldman H, William WN, Xi Y, Basu S, Sun JJ, Yadav SS, Rojas Alvarez FR, Lee Y, Mishra AK, Chen L, Pradhan M, Guo H, Sinjab A, Zhou N, Negrao MV, Le X, Gay CM, Tsao AS, Byers LA, Altan M, Glisson BS, Fossella FV, Elamin YY, Blumenschein G, Zhang J, Skoulidis F, Wu J, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Rajaram R, Antonoff MB, Fujimoto J, Solis LM, Parra ER, Haymaker C, Wistuba II, Swisher SG, Vaporciyan AA, Lin HY, Wang J, Gibbons DL, Jack Lee J, Ajami NJ, Wargo JA, Allison JP, Sharma P, Kadara H, Heymach JV, Sepesi B. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med 29(3):593-604, 2023. e-Pub 2023. PMID: 36928818.
45. Hong L, Aminu M, Li S, Lu X, Petranovic M, Saad MB, Chen P, Qin K, Varghese S, Rinsurongkawong W, Rinsurongkawong V, Spelman A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Gandhi SJ, Lin SH, Lee PP, Carter BW, Wu CC, Antonoff MB, Sepesi B, Lewis J, Gibbons DL, Vaporciyan AA, Le X, Jack Lee J, Roy-Chowdhuri S, Routbort MJ, Gainor JF, Heymach JV, Lou Y, Wu J, Zhang J, Vokes NI. Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer. Nat Commun 14(1):695, 2023. e-Pub 2023. PMID: 36755027.
46. Aminu, M, Yadav, D, Hong, L, Young, E, Edelkamp, P, Saad, MB, Salehjahromi, M, Chen, P, Sujit, S, Chen, MM, Sabloff, B, Gladish, G, de Groot, P, Godoy, M, Cascone, T, Vokes, N, Zhang, J, Brock, K, Daver, N, Woodman, SE, Tawbi, H, Sheshadri, A, Lee, JJ, Jaffray, D, Wu, CC, Chung, C, Wu, J. Habitat Imaging Biomarkers for Diagnosis and Prognosis in Cancer Patients Infected with COVID-19. Cancers 15(1), 2023. e-Pub 2023. PMID: 36612278.
47. Patel SA, Nilsson MB, Le X, Cascone T, Jain RK, Heymach JV. Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy. Clin Cancer Res 29(1):30-39, 2023. e-Pub 2023. PMID: 35969170.
48. Hao, D, Han, G, Sinjab, A, Gomez Bolanos, L, Segura Lazcano, R, Serrano, A, Hernandez, S, Dai, E, Cao, X, Hu, J, Dang, M, Wang, R, Chu, Y, Song, X, Zhang, J, Parra Cuentas, ER, Wargo, J, Swisher, SG, Cascone, T, Sepesi, B, Futreal, A, Li, M, Dubinett, SM, Fujimoto, J, Solis Soto, LM, Wistuba, II, Stevenson, CS, Spira, A, Shalapour, S, Kadara, HN, Wang, L. The Single-Cell Immunogenomic Landscape of B and Plasma Cells in Early-Stage Lung Adenocarcinoma. Cancer discovery 12(11):2626-2645, 2022. e-Pub 2022. PMID: 36098652.
49. Pataer A, Weissferdt A, Correa AM, Vaporciyan AA, Sepesi B, Heymach JV, Berezowska S, Cascone T, Swisher SG. Major Pathologic Response and Prognostic Score Predict Survival in Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy. JTO Clin Res Rep 3(11):100420, 2022. e-Pub 2022. PMID: 36389133.
50. Sepesi B, Zhou N, William WN, Lin HY, Leung CH, Weissferdt A, Mitchell KG, Pataer A, Walsh GL, Rice DC, Roth JA, Mehran RJ, Hofstetter WL, Antonoff MB, Rajaram R, Negrao MV, Tsao AS, Gibbons DL, Lee JJ, Heymach JV, Vaporciyan AA, Swisher SG, Cascone T. Surgical outcomes after nivolumab or nivolumab with ipilimumab treatment in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg 164(5):1327-1337, 2022. e-Pub 2022. PMID: 35190177.
51. Skoulidis F, Heymach JV, Cascone T. A STING operation to expose KRAS and STK11 co-mutated lung cancers. Cancer Cell 40(10):1073-1076, 2022. e-Pub 2022. PMID: 36220070.
52. Liang W, Cai K, Cao Q, Chen C, Chen H, Chen J, Chen KN, Chen Q, Chu T, Dong Y, Fan J, Fang W, Fu J, Fu X, Gao S, Ge D, Geng G, Geng Q, He J, Hu J, Hu J, Hu WD, Jiang F, Jiang T, Jiao W, Li HC, Li Q, Li S, Li S, Li X, Liao YD, Liu C, Liu H, Liu Y, Lu Z, Luo Q, Ma H, Pan X, Qiao G, Ren S, Shen W, Song Y, Sun D, Wang G, Wang J, Wang M, Wang Q, Wang WX, Wei L, Wu M, Wu N, Xia H, Xu SD, Yang F, Yang K, Yang Y, Yu F, Yu ZT, Yue DS, Zhang L, Zhang W, Zhang Z, Zhao G, Zhao J, Zhao X, Zhou C, Zhou Q, Zhu K, Zhu Y, Hida T, Dempke WCM, Rossi A, de Perrot M, Ramirez RA, Provencio M, Lee JM, Passaro A, Spaggiari L, Spicer J, Girard N, Forde PM, Mok TSK, Cascone T, He J. International expert consensus on immunotherapy for early-stage non-small cell lung cancer. Transl Lung Cancer Res 11(9):1742-1762, 2022. e-Pub 2022. PMID: 36248334.
53. Elamin YY, Robichaux JP, Carter BW, Altan M, Tran H, Gibbons DL, Heeke S, Fossella FV, Lam VK, Le X, Negrao MV, Nilsson MB, Patel A, Vijayan RSK, Cross JB, Zhang J, Byers LA, Lu C, Cascone T, Feng L, Luthra R, San Lucas FA, Mantha G, Routbort M, Blumenschein G, Tsao AS, Heymach JV. Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Cancer Cell 40(7):754-767.e6, 2022. e-Pub 2022. PMID: 35820397.
54. Schmidt ST, Akhave N, Knightly RE, Reuben A, Vokes N, Zhang J, Li J, Fujimoto J, Byers LA, Sanchez-Espiridion B, Diao L, Wang J, Federico L, Forget MA, McGrail DJ, Weissferdt A, Lin SY, Lee Y, Suzuki E, Kovacs JJ, Behrens C, Wistuba II, Futreal A, Vaporciyan A, Sepesi B, Heymach JV, Bernatchez C, Haymaker C, Cascone T, Zhang J, Bristow CA, Heffernan TP, Negrao MV, Gibbons DL, Team I. Shared Nearest Neighbors Approach and Interactive Browser for Network Analysis of a Comprehensive Non-Small-Cell Lung Cancer Data Set. JCO Clin Cancer Inform 6:e2200040, 2022. e-Pub 2022. PMID: 35944232.
55. Burton EM, Amaria RN, Cascone T, Chalabi M, Gross ND, Mittendorf EA, Scolyer RA, Sharma P, Ascierto PA. Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge-December 1st-2nd, 2021. J Transl Med 20(1):271, 2022. e-Pub 2022. PMID: 35706041.
56. Schmidt ST, Akhave N, Knightly RE, Reuben A, Vokes N, Zhang J, Li J, Fujimoto J, Byers LA, Sanchez-Espiridion B, Diao L, Wang J, Federico L, Forget MA, McGrail DJ, Weissferdt A, Lin SY, Lee Y, Suzuki E, Kovacs JJ, Behrens C, Wistuba II, Futreal A, Vaporciyan AA, Sepesi B, Heymach JV, Bernatchez C, Haymaker C, Cascone T, Zhang J, Bristow CA, Heffernan TP, Negrao MV, Gibbons, DL, ICON team AT. A shared nearest neighbors approach and interactive browser for network analysis of a comprehensive non-small cell lung cancer dataset, 2022. e-Pub 2022.
57. Rocha P, Zhang J, Laza-Briviesca R, Cruz-Bermúdez A, Bota-Rabassedas N, Sanchez-Espiridon B, Yoshimura K, Behrens C, Lu W, Tang X, Pataer A, Parra ER, Haymaker C, Fujimoto J, Swisher SG, Heymach JV, Gibbons DL, Lee JJ, Sepesi B, T |, Solis LM, Provencio M, Wistuba II, Kadara H. Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC. Clin Cancer Res 28(11):2461-2473, 2022. e-Pub 2022. PMID: 35394499.
58. Cascone T, Chelvanambi M, Wargo JA. Immunotherapy response-associated Akkermansia: canary in a coal mine?. Trends Immunol 43(5):337-339, 2022. e-Pub 2022. PMID: 35397955.
59. Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumenschein GR, Altan M, Lim B, Valero V, Loghin ME, Tu J, Westin SN, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi HA, Hwu P, Oliva ICG, Davies MA, Patel SP, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun 13(1):1970, 2022. e-Pub 2022. PMID: 35413951.
60. Mittendorf EA, Burgers F, Haanen J, b|| CT. Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease. Am Soc Clin Oncol Educ Book 42:1-15, 2022. e-Pub 2022. PMID: 35714302.
61. Deboever N, McGrail DJ, Lee Y, Tran HT, Mitchell KG, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Bernatchez C, Vailati Negrao M, Zhang J, Wistuba II, Heymach JV, Cascone T, Gibbons DL, Haymaker CL, Sepesi B. Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection. Lung Cancer 164:69-75, 2022. e-Pub 2022. PMID: 35038676.
62. Shah P, Forget MA, Frank ML, Jiang P, Sakellariou-Thompson D, Federico L, Khairullah R, Neutzler CA, Wistuba I, Chow CB, Long Y, Fujimoto J, Lin SY, Maitra A, Negrao MV, Mitchell KG, Weissferdt A, Vaporciyan AA, Cascone T, Roth JA, Zhang J, Sepesi B, Gibbons DL, Heymach JV, Haymaker CL, McGrail DJ, Reuben A, Bernatchez C. Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. J Immunother Cancer 10(2), 2022. e-Pub 2022. PMID: 35110355.
63. Deboever N, Mitchell KG, Feldman HA, Cascone T, Sepesi B. Current Surgical Indications for Non-Small-Cell Lung Cancer. Cancers (Basel) 14(5), 2022. e-Pub 2022. PMID: 35267572.
64. Patel SA, Herynk MH, Cascone T, Saigal B, Nilsson MB, Tran H, Ramachandran S, Diao L, Wang J, Le X, Minna J, Wistuba II, Heymach JV. Estrogen Promotes Resistance to Bevacizumab in Murine Models of NSCLC. J Thorac Oncol 16(12):2051-2064, 2021. e-Pub 2021. PMID: 34311109.
65. Gudikote JP, Cascone T, Poteete A, Sitthideatphaiboon P, Wu Q, Morikawa N, Zhang F, Peng S, Tong P, Li L, Shen L, Nilsson M, Jones P, Sulman EP, Wang J, Bourdon JC, Johnson FM, Heymach JV. Inhibition of nonsense-mediated decay rescues p53β/γ isoform expression and activates the p53 pathway in MDM2-overexpressing and select p53-mutant cancers. J Biol Chem 297(5):101163, 2021. e-Pub 2021. PMID: 34481841.
66. Sinjab A, Han G, Treekitkarnmongkol W, Hara K, Brennan PM, Dang M, Hao D, Wang R, Dai E, Dejima H, Zhang J, Bogatenkova E, Sanchez-Espiridion B, Chang K, Little DR, Bazzi S, Tran LM, Krysan K, Behrens C, Duose DY, Parra ER, Raso MG, Solis LM, Fukuoka J, Zhang J, Sepesi B, Cascone T, Byers LA, Gibbons DL, Chen J, Moghaddam SJ, Ostrin EJ, Rosen D, Heymach JV, Scheet P, Dubinett SM, Fujimoto J, Wistuba II, Stevenson CS, Spira A, Wang L, Kadara H. Resolving the spatial and cellular architecture of lung adenocarcinoma by multiregion single-cell sequencing. Cancer Discov 11(10):2506-2523, 2021. e-Pub 2021. PMID: 33972311.
67. Federico L, McGrail DJ, Bentebibel SE, Haymaker C, Ravelli A, Forget MA, Karpinets T, Jiang P, Reuben A, Negrao MV, Li J, Khairullah R, Zhang J, Weissferdt A, Vaporciyan AA, Antonoff MB, Walsh G, Lin SY, Futreal A, Wistuba I, Roth J, Byers LA, Gaudreau PO, Uraoka N, Cruz AF, Dejima H, Lazcano RN, Solis LM, Parra ER, Lee JJ, Swisher S, Cascone T, Heymach JV, Zhang J, Sepesi B, Gibbons DL, Bernatchez C. Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer. Ann Oncol. e-Pub 2021. PMID: 34653632.
68. Shu CA, Cascone T. What Is Neo? Chemoimmunotherapy in the Neoadjuvant Setting for Resectable Non-Small-Cell Lung Cancer. J Clin Oncol 39(26):2855-2858, 2021. e-Pub 2021. PMID: 34339287.
69. Chaft JE, Rimner A, Weder W, Azzoli CG, Kris MG, T||B C. Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer. Nat Rev Clin Oncol 18(9):547-557, 2021. e-Pub 2021. PMID: 33911215.
70. Negrao MV, Skoulidis F, Montesion M, Schulze K, Bara I, Shen V, Xu H, Hu S, Sui D, Elamin YY, Le X, Goldberg ME, Murugesan K, Wu CJ, Zhang J, Barreto DS, Robichaux JP, Reuben A, Cascone T, Gay CM, Mitchell KG, Hong L, Rinsurongkawong W, Roth JA, Swisher SG, Lee J, Tsao A, Papadimitrakopoulou V, Gibbons DL, Glisson BS, Singal G, Miller VA, Alexander B, Frampton G, Albacker LA, Shames D, Zhang J, Heymach JV. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. J Immunother Cancer 9(8), 2021. e-Pub 2021. PMID: 34376553.
71. Pataer A, Weissferdt A, Vaporciyan AA, Correa AM, Sepesi B, Wistuba II, Heymach JV, Cascone T, Swisher SG. Evaluation of Pathologic Response in Lymph Nodes of Lung Cancer Patients Receiving Neoadjuvant Chemotherapy. J Thorac Oncol 16(8):1289-1297, 2021. e-Pub 2021. PMID: 33857666.
72. Cascone T, Weissferdt A, Godoy MCB, William WN, Leung CH, Lin HY, Basu S, Yadav SS, Pataer A, Mitchell KG, Khan MAW, Shi Y, Haymaker C, Solis LM, Parra ER, Kadara H, Wistuba II, Sharma P, Allison JP, Ajami NJ, Wargo JA, Jenq RR, Gibbons DL, Lee JJ, Swisher SG, Vaporciyan AA, Heymach JV, Sepesi B. Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. Nat Commun 12(1):5045, 2021. e-Pub 2021. PMID: 34413300.
73. Rocha P, Salazar R, Zhang J, Ledesma D, Solorzano JL, Mino B, Villalobos P, Dejima H, Douse DY, Diao L, Mitchell KG, Le X, Zhang J, Weissferdt A, Parra-Cuentas E, Cascone T, Rice DC, Sepesi B, Kalhor N, Moran C, Vaporciyan A, Heymach J, Gibbons DL, Lee JJ, Kadara H, Wistuba I, Behrens C, Solis LM. CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunol Immunother 70(7):1965-1976, 2021. e-Pub 2021. PMID: 33416944.
74. Sepesi B, Cascone T. Will radiotherapy be a future part of neoadjuvant therapy in operable non-small-cell lung cancer?. Lancet Oncol 22(6):744-746, 2021. e-Pub 2021. PMID: 34015310.
75. Subbiah V, Shen T, Tetzlaff M, Weissferdt A, Byers LA, Cascone T, Behrang A, Meric-Bernstam F, Mooers BHM, Rothenberg SM, Ebata K, Wu J. Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer. Ann Oncol 32(6):817-819, 2021. e-Pub 2021. PMID: 33617938.
76. Cascone T, Sacks RL, Subbiah IM, Drobnitzky N, Piha-Paul SA, Hong DS, Hess KR, Amini B, Bhatt T, Fu S, Naing A, Janku F, Karp D, Falchook GS, Conley AP, Sherman SI, Meric-Bernstam F, Ryan AJ, Heymach JV, Subbiah V. Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study. ESMO Open 6(2):100079, 2021. e-Pub 2021. PMID: 33721621.
77. Weissferdt A, Pataer A, Swisher SG, Heymach JV, Gibbons DL, Cascone T, Sepesi B. Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment. Lung Cancer 154:76-83, 2021. e-Pub 2021. PMID: 33631448.
78. Han G, Sinjab A, Hara K, Treekitkarnmongkol W, Brennan P, Chang K, Bogatenkova E, Sanchez-Espiridion B, Behrens C, Solis LM, Gao B, Girard L, Zhang J, Sepesi B, Cascone T, Byers LA, Gibbons DL, Chen J, Moghaddam SJ, Ostrin EJ, Scheet P, Fujimoto J, Shay J, Heymach JV, Minna JD, Dubinett S, Wistuba II, Stevenson CS, Spira AE, Wang L, Kadara H. Single-Cell Expression Landscape of SARS-CoV-2 Receptor ACE2 and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients. Cancers (Basel) 13(6), 2021. e-Pub 2021. PMID: 33809063.
79. Cascone T, William WN, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi B. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med 27(3):504-514, 2021. e-Pub 2021. PMID: 33603241.
80. Nilsson MB, Robichaux J, Herynk MH, Cascone T, Le X, Elamin Y, Patel S, Zhang F, Xu L, Hu L, Diao L, Shen L, He J, Yu X, Nikolinakos P, Saintigny P, Fang B, Girard L, Wang J, Minna JD, Wistuba II, Heymach JV. Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype. J Thorac Oncol 16(3):439-451, 2021. e-Pub 2021. PMID: 33309987.
81. Corsini EM, Weissferdt A, Pataer A, Zhou N, Antonoff MB, Hofstetter WL, Mehran RJ, Rajaram R, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Cascone T, Heymach JV, Swisher SG, Sepesi B. Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy. Eur J Cardiothorac Surg 59(1):100-108, 2021. e-Pub 2021. PMID: 32864702.
82. Treekitkarnmongkol W, Hassane M, Sinjab A, Chang K, Hara K, Rahal Z, Zhang J, Lu W, Sivakumar S, McDowell TL, Kantrowitz J, Zhou J, Lang W, Xu L, Ochieng JK, Nunomura-Nakamura S, Deng S, Behrens C, Raso MG, Fukuoka J, Reuben A, Ostrin EJ, Parra E, Solis LM, Spira AE, McAllister F, Cascone T, Wistuba II, Moghaddam SJ, Scheet PA, Fujimoto J, Kadara H. Augmented Lipocalin-2 Is Associated with Chronic Obstructive Pulmonary Disease and Counteracts Lung Adenocarcinoma Development. Am J Respir Crit Care Med 203(1):90-101, 2021. e-Pub 2021. PMID: 32730093.
83. Gaudreau PO, Negrao MV, Mitchell KG, Reuben A, Corsini EM, Li J, Karpinets TV, Wang Q, Diao L, Wang J, Federico L, Parra-Cuentas ER, Khairullah R, Behrens C, Correa AM, Gomez D, Little L, Gumbs C, Kadara HN, Fujimoto J, McGrail DJ, Vaporciyan AA, Swisher SG, Walsh G, Antonoff MB, Weissferdt A, Tran H, Roarty E, Haymaker C, Bernatchez C, Zhang J, Futreal PA, Wistuba II, Cascone T, Heymach JV, Sepesi B, Zhang J, Gibbons DL. Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC. J Thorac Oncol 16(1):127-139, 2021. e-Pub 2021. PMID: 33096269.
84. Pradhan M, Chocry M, Gibbons DL, Sepesi B, Cascone T. Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer. Transl Lung Cancer Res 10(1):590-606, 2021. e-Pub 2021. PMID: 33569339.
85. Sepesi B, Cascone T, Chun SG, Altan M, Le X. Emerging Therapies in Thoracic Malignancies-Immunotherapy, Targeted Therapy, and T-Cell Therapy in Non-Small Cell Lung Cancer. Surg Oncol Clin N Am 29(4):555-569, 2020. e-Pub 2020. PMID: 32883458.
86. Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, Mitchell KG, Tran HT, Le X, Byers LA, Sepesi B, Altan M, Elamin YY, Fossella FV, Kurie JM, Lu C, Mott FE, Tsao AS, Rinsurongkawong W, Lewis J, Gibbons DL, Glisson BS, Blumenschein GR, Roarty EB, Futreal PA, Wistuba II, Roth JA, Swisher SG, Papadimitrakopoulou VA, Heymach JV, Lee JJ, Simon GR, Zhang J. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol 15(9):1449-1459, 2020. e-Pub 2020. PMID: 32389639.
87. Corsini EM, Wang Q, Tran HT, Mitchell KG, Antonoff MB, Hofstetter WL, Mehran RJ, Rice DC, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Reuben A, Vasquez ME, Bernatchez C, Wang J, Cascone T, Zhang J, Heymach JV, Gibbons DL, Haymaker CL, Sepesi B. Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively. Lung Cancer 146:303-309, 2020. e-Pub 2020. PMID: 32619781.
88. Mitchell KG, Amini B, Wang Y, Carter BW, Godoy MCB, Parra ER, Behrens C, Villalobos P, Reuben A, Lee JJ, Weissferdt A, Moran CA, Fujimoto J, Sepesi B, Walsh GL, Vaporciyan AA, Hofstetter WL, William WN, Gibbons DL, Wang J, Hwu P, Swisher SG, Piwnica-Worms D, Kadara H, Wistuba II, Heymach JV, Peng W, Cascone T. 18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. Cancer Immunol Immunother 69(8):1519-1534, 2020. e-Pub 2020. PMID: 32300858.
89. Weissferdt A, Pataer A, Vaporciyan AA, Correa AM, Sepesi B, Moran CA, Wistuba II, Roth JA, Shewale JB, Heymach JV, Kalhor N, Cascone T, Hofstetter WL, Lee JJ, Swisher SG. Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy. Clin Lung Cancer 21(4):341-348, 2020. e-Pub 2020. PMID: 32279936.
90. Cascone T, Sepesi B, Lin HY, Kalhor N, Parra ER, Jiang M, Godoy MCB, Zhang J, Fossella FV, Tsao AS, Lam VK, Lu C, Mott FE, Simon GR, Antonoff MB, Mehran RJ, Rice DC, Behrens C, Weissferdt A, Moran C, Vaporciyan AA, Lee JJ, Swisher SG, Gibbons DL, Wistuba II, William WN, Heymach JV. A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clin Cancer Res 26(14):3525-3536, 2020. e-Pub 2020. PMID: 32193228.
91. Rajaram R, Correa AM, Xu T, Nguyen QN, Antonoff MB, Rice D, Mehran R, Roth J, Walsh G, Swisher S, Hofstetter WL, Vaporciyan A, Cascone T, Tsao AS, Papadimitrakopoulou VA, Gandhi S, Liao Z, Sepesi B. Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients. Clin Lung Cancer 21(4):e294-e301, 2020. e-Pub 2020. PMID: 32089476.
92. Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, Chou TY, Cooper W, Erasmus JJ, Ferreira CG, Goo JM, Heymach J, Hirsch FR, Horinouchi H, Kerr K, Kris M, Jain D, Kim YT, Lopez-Rios F, Lu S, Mitsudomi T, Moreira A, Motoi N, Nicholson AG, Oliveira R, Papotti M, Pastorino U, Paz-Ares L, Pelosi G, Poleri C, Provencio M, Roden AC, Scagliotti G, Swisher SG, Thunnissen E, Tsao MS, Vansteenkiste J, Weder W, Yatabe Y. IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY. J Thorac Oncol 15(5):709-740, 2020. e-Pub 2020. PMID: 32004713.
93. Mitchell KG, Diao L, Karpinets T, Negrao MV, Tran HT, Parra ER, Corsini EM, Reuben A, Federico L, Bernatchez C, Dejima H, Francisco-Cruz A, Wang J, Antonoff MB, Vaporciyan AA, Swisher SG, Cascone T, Wistuba II, Heymach JV, Gibbons DL, Zhang J, Haymaker CL, Sepesi B. Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort. J Immunother Cancer 8(1), 2020. e-Pub 2020. PMID: 32350118.
94. Sepesi B, Cascone T. Commentary: Neoadjuvant checkpoint inhibitors in resectable non-small cell lung cancer-Ready for prime time?. J Thorac Cardiovasc Surg 159(4):1624-1625, 2020. e-Pub 2020. PMID: 31648835.
95. Mitchell KG, Negrao MV, Parra ER, Li J, Zhang J, Dejima H, Vaporciyan AA, Swisher SG, Weissferdt A, Antonoff MB, Cascone T Roarty E, Wistuba II, Heymach JV, Gibbons DL, Zhang J, Sepesi B. Lymphovascular Invasion Is Associated with Mutational Burden and PD-L1 in Resected Lung Cancer. Ann Thorac Surg 109(2):358-366, 2020. e-Pub 2020. PMID: 31550464.
96. Reuben A, Zhang J, Chiou SH, Gittelman RM, Li J, Lee WC, Fujimoto J, Behrens C, Liu X, Wang F, Quek K, Wang C, Kheradmand F, Chen R, Chow CW, Lin H, Bernatchez C, Jalali A, Hu X, Wu CJ, Eterovic AK, Parra ER, Yusko E, Emerson R, Benzeno S, Vignali M, Wu X, Ye Y, Little LD, Gumbs C, Mao X, Song X, Tippen S, Thornton RL, Cascone T, Snyder A, Wargo JA, Herbst R, Swisher S, Kadara H, Moran C, Kalhor N, Zhang J, Scheet P, Vaporciyan AA, Sepesi B, Gibbons DL, Robins H, Hwu P, Heymach JV, Sharma P, Allison JP, Baladandayuthapani V, Lee JJ, Davis MM, Wistuba II, Futreal PA, Zhang J. Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat Commun 11(1):603, 2020. e-Pub 2020. PMID: 32001676.
97. Simon G, DiNardo CD, Takahashi K, Cascone T, Powers C, Stevens R, Allen J, Antonoff MB, Gomez D, Keane P, Suarez Saiz F, Nguyen Q, Roarty E, Pierce S, Zhang J, Hardeman Barnhill E, Lakhani K, Shaw K, Smith B, Swisher S, High R, Futreal PA, Heymach J, Chin L. Applying Artificial Intelligence to Address the Knowledge Gaps in Cancer Care. Oncologist 24(6):772-782, 2019. e-Pub 2019. PMID: 30446581.
98. Chen L, Diao L, Yang Y, Yi X, Rodriguez BL, Li Y, Villalobos PA, Cascone T Liu X, Tan L, Lorenzi PL, Huang A, Zhao Q, Peng D, Fradette JJ, Peng DH, Ungewiss C, Roybal J, Tong P, Oba J, Skoulidis F, Peng W, Carter BW, Gay CM, Fan Y, Class CA, Zhu J, Rodriguez-Canales J, Kawakami M, Byers LA, Woodman SE, Papadimitrakopoulou VA, Dmitrovsky E, Wang J, Ullrich SE, Wistuba II, Heymach JV, Qin FX, Gibbons DL. CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade. Cancer Discov 8(9):1156-1175, 2018. e-Pub 2018. PMID: 30012853.
99. Parra ER, Villalobos P, Behrens C, Jiang M, Pataer A, Swisher SG, William WN, Zhang J, Lee J, Cascone T Heymach JV, Forget MA, Haymaker C, Bernatchez C, Kalhor N, Weissferdt A, Moran C, Zhang J, Vaporciyan A, Gibbons DL, Sepesi B, Wistuba II. Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. J Immunother Cancer 6(1):48, 2018. e-Pub 2018. PMID: 29871672.
100. Lee WC, Diao L, Wang J, Zhang J, Roarty EB, Varghese S, Chow CW, Fujimoto J, Behrens C, Cascone T Peng W, Kalhor N, Moran CA, Weissferdt A, Johnson FM, William WN, Swisher SG, Lee JJ, Hong WK, Heymach JV, Wistuba II, Futreal PA, Zhang J. Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. Mod Pathol 31(6):947-955, 2018. e-Pub 2018. PMID: 29410488.
101. Cascone T McKenzie JA, Mbofung RM, Punt S, Wang Z, Xu C, Williams LJ, Wang Z, Bristow CA, Carugo A, Peoples MD, Li L, Karpinets T, Huang L, Malu S, Creasy C, Leahey SE, Chen J, Chen Y, Pelicano H, Bernatchez C, Gopal YNV, Heffernan TP, Hu J, Wang J, Amaria RN, Garraway LA, Huang P, Yang P, Wistuba II, Woodman SE, Roszik J, Davis RE, Davies MA, Heymach JV, Hwu P, Peng W. Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. Cell Metab 27(5):977-987.e4, 2018. e-Pub 2018. PMID: 29628419.
102. Cascone T Gold KA, Swisher SG, Liu DD, Fossella FV, Sepesi B, Pataer A, Weissferdt A, Kalhor N, Vaporciyan AA, Hofstetter WL, Wistuba II, Heymach JV, Kim ES, William WN. Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer. Ann Thorac Surg 105(2):418-424, 2018. e-Pub 2018. PMID: 29217088.
103. Reuben A, Gittelman R, Gao J, Zhang J, Yusko EC, Wu CJ, Emerson R, Zhang J, Tipton C, Li J, Quek K, Gopalakrishnan V, Chen R, Vence LM, Cascone T Vignali M, Fujimoto J, Rodriguez-Canales J, Parra ER, Little LD, Gumbs C, Forget MA, Federico L, Haymaker C, Behrens C, Benzeno S, Bernatchez C, Sepesi B, Gibbons DL, Wargo JA, William WN, Swisher S, Heymach JV, Robins H, Lee JJ, Sharma P, Allison JP, Futreal PA, Wistuba II, Zhang J. TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discov 7(10):1088-1097, 2017. e-Pub 2017. PMID: 28733428.
104. Cascone T, Xu L, Lin HY, Liu W, Tran HT, Liu Y, Howells K, Haddad V, Hanrahan E, Nilsson MB, Cortez MA, Giri U, Kadara H, Saigal B, Park YY, Peng W, Lee JS, Ryan AJ, Jüergensmeier JM, Herbst RS, Wang J, Langley RR, Wistuba II, Lee JJ, Heymach JV. The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer. Clin Cancer Res 23(18):5489-5501, 2017. e-Pub 2017. PMID: 28559461.
105. Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres-Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T Li HS, Kwong LN, Heffernan TP, Hu J, Bassett RL, Bosenberg MW, Woodman SE, Overwijk WW, Lizée G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi L, Davies MA, Hwu P. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov 6(2):202-16, 2016. e-Pub 2016. PMID: 26645196.
106. Cascone T Heymach JV. Can the Lung Cancer Pie Be Divided into Angiogenic Slices?. Clin Cancer Res 21(23):5188-90, 2015. e-Pub 2015. PMID: 26232370.
107. Subbiah V, Berry J, Roxas M, Guha-Thakurta N, Subbiah IM, Ali SM, McMahon C, Miller V, Cascone T, Pai S, Tang Z, Heymach JV. Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases. Lung Cancer 89(1):76-9, 2015. e-Pub 2015. PMID: 25982012.
108. Mehran R, Nilsson M, Khajavi M, Du Z, Cascone T, Wu HK, Cortes A, Xu L, Zurita A, Schier R, Riedel B, El-Zein R, Heymach JV. Tumor endothelial markers define novel subsets of cancer-specific circulating endothelial cells associated with antitumor efficacy. Cancer Res 74(10):2731-41, 2014. e-Pub 2014. PMID: 24626092.
109. Seguin L, Kato S, Franovic A, Camargo MF, Lesperance J, Elliott KC, Yebra M, Mielgo A, Lowy AM, Husain H, Cascone T Diao L, Wang J, Wistuba II, Heymach JV, Lippman SM, Desgrosellier JS, Anand S, Weis SM, Cheresh DA. An integrin β3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat Cell Biol 16(5):457-68, 2014. e-Pub 2014. PMID: 24747441.
110. Wagner KW, Alam H, Dhar SS, Giri U, Li N, Wei Y, Giri D, Cascone T Kim JH, Ye Y, Multani AS, Chan CH, Erez B, Saigal B, Chung J, Lin HK, Wu X, Hung MC, Heymach JV, Lee MG. KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling. J Clin Invest 123(12):5231-46, 2013. e-Pub 2013. PMID: 24200691.
111. Bhardwaj V, Cascone T Cortez MA, Amini A, Evans J, Komaki RU, Heymach JV, Welsh JW. Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy. Cancer 119(10):1768-75, 2013. e-Pub 2013. PMID: 23423860.
112. Cascone T, Heymach JV. Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword?. J Clin Oncol 30(4):441-4, 2012. e-Pub 2012. PMID: 22184396.
113. Larsen JE, Cascone T Gerber DE, Heymach JV, Minna JD. Targeted therapies for lung cancer: clinical experience and novel agents. Cancer J 17(6):512-27, 2011. e-Pub 2011. PMID: 22157296.
114. Morgillo F, Cascone T, D'Aiuto E, Martinelli E, Troiani T, Saintigny P, De Palma R, Heymach JV, Berrino L, Tuccillo C, Ciardiello F. Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors. Br J Cancer 105(3):382-92, 2011. e-Pub 2011. PMID: 21750552.
115. Cascone T, Herynk MH, Xu L, Du Z, Kadara H, Nilsson MB, Oborn CJ, Park YY, Erez B, Jacoby JJ, Lee JS, Lin HY, Ciardiello F, Herbst RS, Langley RR, Heymach JV. Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. J Clin Invest 121(4):1313-28, 2011. e-Pub 2011. PMID: 21436589.
116. Nilsson MB, Zage PE, Zeng L, Xu L, Cascone T, Wu HK, Saigal B, Zweidler-McKay PA, Heymach JV. Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors. Oncogene 29(20):2938-49, 2010. e-Pub 2010. PMID: 20208561.
117. Xu L, Nilsson MB, Saintigny P, Cascone T, Herynk MH, Du Z, Nikolinakos PG, Yang Y, Prudkin L, Liu D, Lee JJ, Johnson FM, Wong KK, Girard L, Gazdar AF, Minna JD, Kurie JM, Wistuba II, Heymach JV. Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells. Oncogene 29(18):2616-27, 2010. e-Pub 2010. PMID: 20154724.
118. Gridelli C, Morabito A, Gebbia V, Mencoboni M, Carrozza F, Viganò MG, Verusio C, Bollina R, Mattioli R, Valerio MR, Valmadre G, Maione P, Rossi A, Cascone T Morgillo F, Di Maio M, Piccirillo MC, Gallo C, Perrone F, Ciardiello F. Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials. Lung Cancer 67(1):86-92, 2010. e-Pub 2010. PMID: 19380175.
119. Byers LA, Sen B, Saigal B, Diao L, Wang J, Nanjundan M, Cascone T Mills GB, Heymach JV, Johnson FM. Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clin Cancer Res 15(22):6852-61, 2009. e-Pub 2009. PMID: 19861436.
120. Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, Lifshits E, Byers LA, Xu L, Wu HK, Jänne P, Kobayashi S, Halmos B, Tenen D, Tang XM, Engelman J, Yeap B, Folkman J, Johnson BE, Heymach JV. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res 15(10):3484-94, 2009. e-Pub 2009. PMID: 19447865.
121. Cascone T, Morelli MP, Morgillo F, Kim WY, Rodolico G, Pepe S, Tortora G, Berrino L, Lee HY, Heymach JV, Ciardiello F. Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells. J Cell Physiol 216(3):698-707, 2008. e-Pub 2008. PMID: 18381602.
122. Iovino F, Ferraraccio F, Orditura M, Antoniol G, Morgillo F, Cascone T, Diadema MR, Aurilio G, Santabarbara G, Ruggiero R, Belli C, Irlandese E, Fasano M, Ciardiello F, Procaccini E, Lo Schiavo F, Catalano G, De Vita F. Serum vascular endothelial growth factor (VEGF) levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer. Cancer Invest 26(3):250-5, 2008. e-Pub 2008. PMID: 18317965.
123. Cascone T, Martinelli E, Morelli MP, Morgillo F, Troiani T, Ciardiello F. Epidermal growth factor receptor inhibitors in non-small-cell lung cancer. Expert Opin Drug Discov 2(3):335-48, 2007. e-Pub 2007. PMID: 23484645.
124. Cascone T, Gridelli C, Ciardiello F. Combined targeted therapies in non-small cell lung cancer: a winner strategy?. Curr Opin Oncol 19(2):98-102, 2007. e-Pub 2007. PMID: 17272980.
125. Morelli MP, Cascone T, Troiani T, Tuccillo C, Bianco R, Normanno N, Romano M, Veneziani BM, Fontanini G, Eckhardt SG, De Pacido S, Tortora G, Ciardiello F. Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. J Cell Physiol 208(2):344-53, 2006. e-Pub 2006. PMID: 16688779.
126. Ciardiello F, Troiani T, Bianco R, Orditura M, Morgillo F, Martinelli E, Morelli MP, Cascone T Tortora G. Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy. Ann Oncol 17 Suppl 7:vii109-14, 2006. e-Pub 2006. PMID: 16760272.
127. Cascone T, Troiani T, Morelli MP, Gridelli C, Ciardiello F. Antiangiogenic drugs in non-small cell lung cancer treatment. Curr Opin Oncol 18(2):151-5, 2006. e-Pub 2006. PMID: 16462184.
128. Cascone T, Morelli MP, Ciardiello F. Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer. Ann Oncol 17 Suppl 2:ii46-48, 2006. e-Pub 2006. PMID: 16608981.
129. Morelli MP, Cascone T, Troiani T, De Vita F, Orditura M, Laus G, Eckhardt SG, Pepe S, Tortora G, Ciardiello F. Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. Ann Oncol 16 Suppl 4:iv61-68, 2005. e-Pub 2005. PMID: 15923432.

Invited Articles

1. Cascone T, Jr WW. Perioperative nivolumab results in favourable long-term outcomes in patients with locally advanced resectable non-small-cell lung cancer, 2024. e-Pub 2024. PMID: 39627503.
2. Skoulidis F, Heymach JV, Cascone T. A STING operation to expose KRAS and STK11 co-mutated lung cancers. Cancer Cell, 2022. e-Pub 2022. PMID: 36220070.
3. Cascone T, Fradette J, Pradhan M, Gibbons DL. Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer. Cold Spring Harb Perspect Med 12(5), 2022. e-Pub 2022. PMID: 34580079.
4. Sepesi B, Cascone T. Will radiotherapy be a future part of neoadjuvant therapy in operable non-small-cell lung cancer?, 2021. e-Pub 2021. PMID: 34015310.
5. Chaft JE, Rimner A, Weder W, Azzoli CG, Kris MG, Cascone T. Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer, 2021. e-Pub 2021.
6. Shu CA, Cascone T. What Is Neo? Chemoimmunotherapy in the Neoadjuvant Setting for Resectable Non-Small-Cell Lung Cancer, 2021. e-Pub 2021.
7. Sepesi B, Cascone T, Chun SG, Altan M, Le X. Emerging Therapies in Thoracic Malignancies-Immunotherapy, Targeted Therapy, and T-Cell Therapy in Non-Small Cell Lung Cancer, 2020. e-Pub 2020.
8. Cascone T, Heymach JV. Can the lung cancer pie be divided in angiogenic slices?. Clinical Cancer Research, 2015. e-Pub 2015.
9. Cascone T, and Heymach JV. The Ang/Tie2 pathway: cutting the tumor vessels with a double edge sword?. J Clin Oncol, 2012. e-Pub 2012.
10. Cascone T, Subbiah V, Heymach JV. Inhibitors for the treatment of RET-rearranged Non-small cell lung cancer.

Review Articles

1. Vaccaro A, Rahal Z, Kadara H, Cascone T. A Roadmap to Precision Immunotherapy for Early-Stage Non-Small Cell Lung Cancer. Cancer Discov 15(5):884-889, 2025. e-Pub 2025. PMID: 39997992.
2. Mountzios G, Saw SPL, Hendriks L, Menis J, Cascone T, Arrieta O, Naidoo J, Koutoukoglou P, Cani M, Lefevre A, Addeo A, Peters S, Remon J. Antibody-drug conjugates in NSCLC with actionable genomic alterations: Optimizing smart delivery of chemotherapy to the target. Cancer Treat Rev 134:102902, 2025. e-Pub 2025. PMID: 39978083.

Other Articles

1. Cascone, T Expert Point of View: Tina Cascone, MD, PhD, Discussant of the Neotorch study. The ASCO Post, 2023.
2. Center News TUOTMAC Physician Scientists Program helps clinicians build strong research careers, 2023.
3. Cascone, T Neoadjuvant Dual Immunotherapy Plus Chemotherapy Improves Patient Outcomes in Operable Lung Cancer, 2023.
4. Cascone, T Neoadjuvant Ipilimumab + Nivolumab + Chemotherapy Enhances Pathologic Responses. Cancer Discovery Research Watch, 2023.
5. Cascone, T T Testing New Neoadjuvant Combos in NSCLC. News in Brief, 2022.
6. Cascone, T T The New Frontier of Immunotherapy in Lung Cancer - Boosting the Immune Response Before Surgery, 2022.
7. Cascone, T T Novel Neoadjuvant Therapy May Boost Response in Resectable NSCLC, 2022.
8. Cascone, T T New Findings From the NeoCOAST Trial on Durvalumab-Based Therapy, 2022.
9. Cascone, T T Boosting Responses to Neoadjuvant Therapy in Resectable NSCLC, 2022.
10. Cascone, T T Women Leadership Celebration Issue, The Conference Forum, 2022.
11. Cascone, T Neoadjuvant immunotherapy for resectable non-small cell lung cancer: Murine models to clinical trials, 2021.
12. Cascone, T T Combo Immunotherapy Improves Outcomes for Early-Stage NSCLC. Oncology Times 43(12):1, 11-12, 2021.
13. Cascone, T Evaluating Adjuvant Immunotherapy Use in Resected Stage IB-IIIA NSCLC, 2021.
14. Cascone, T T, Ajami N, Wargo JA Neoadjuvant ICI Response, Microbiome Probed in NSCLC, 2021.
15. Cascone, T T Combination immunotherapy treatment effective before lung cancer surgery, 2021.
16. Cascone, T T Phase II randomised study met prespecified primary endpoint threshold in patients with operable non-small cell lung cancer, 2021.
17. Cascone, T T, Sepesii B Neoadjuvant combination immunotherapy improves outcomes for early stage non-small cell lung cancer, 2021.
18. Cascone, T T, Sepesii B Neoadjuvant immunotherapy can produce nodal immune flair in lung cancer, 2021.
19. Cascone, T T AACR 2022: Neoadjuvant Durvalumab Alone or in Combination for Early-Stage Lung Cancer, 2021.
20. Cascone, T T Neoadjuvant Dual ICI Leads to Clinical Benefit in Operable NSCLC, 2021.
21. Cascone, T T Study reveals promising, less toxic treatments for patients with lung cancer, 2021.
22. T C, and Sepesi B MD Anderson researchers present immunotherapy advances at Society for Immunotherapy of Cancer Annual Meeting. Highlights include positive clinical data from combination therapies in patients with melanoma and lung cancer, 2020.
23. Cascone, T Adjuvant Osimertinib Extends DFS in Localized NSCLC, 2020.
24. Cascone, T T Remaining Challenges With Perioperative Immunotherapy in NSCLC, 2019.
25. Cascone, T T Nivo/ipi shrinks early NSCLC before surgery, 2019.
26. Cascone, T T Combination Checkpoint Blockade for Early-Stage Non–Small-Cell Lung Cancer, 2019.
27. Cascone, T T Combination checkpoint blockade effective in pre-surgical setting for early-stage lung cancers, 2019.
28. Cascone, T T Neoadjuvant Nivolumab/Ipilimumab Shows Promise in Resectable NSCLC, 2019.
29. Cascone, T T Toxicity Of Nivolumab & Ipilimumab: Were Still Learning How To Leverage These Treatments In The Pre-Operative Setting, 2019.
30. Cascone, T T Clinical and translational results from the NEOSTAR study: Treating early-stage lung cancer with nivolumab plus ipilimumab, 2019.
31. Cascone, T T Priming Immune System Prior to Surgery May Improve Outcomes. Oncology Times 40(15):22, 31, 2016.
32. Cascone, T T Career Spotlight: What I Do As A Cancer Researcher. Lifehacker, 2016.

Editorials

1. Cascone T, Subbiah V, Heymach JV. RET Inhibitors for the treatment of RET-rearranged Non-small cell lung cancer. ASCO Daily News Expert Editorial, 2017.

Abstracts

1. Cascone T, Provencio M, Awad MM, Spicer J, Janssens A, Moiseenko FV, Gao Y, Watanabe Y, Alexandru A, Guisier F, Frost N, Franke FA, TJJN H, He J, Tanaka F, Lu S, Coronado Erdmann C, Sathyanarayana P, Tran P, Devas V, Cascone T. Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: Results from the phase 3 CheckMate 77T study. ASCO Annual Meeting 2024, 2024. e-Pub 2024.
2. Cascone T, Awad MM, Spicer J, He J, Lu S, Sepesi B, Tanaka F, Taube JM, Cornelissen R, Havel L, Kuzdzal J, Petruzelka LB, Wu L, Pujol JL, Ito H, Coronado Erdmann C, Sathyanarayana P, Meadows-Shropshire S, Provencio Pulla M. CheckMate 77T: Phase 3 study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIB NSCLC, 2023. e-Pub 2023.
3. Chelvanambi M, Deboever N, Nassif E, Damania AV, Chen L, Leung CH, Chin WC, Keung EZ, Witt RG, White MG, Johnson SB, Wong MC, Mishra AK, Lastrapes MJ, Somaiah N, Kadara H, Basu S, Allison JP, Sharma P, McBride KM, Fridman WH, Heymach JV, Sepesi B, Ajami NJ, Roland CL, Wargo JA, Cascone T. Metagenomic sequencing reveals unique gut microbial features associated with tertiary lymphoid structures in response to immune checkpoint blockade in solid cancers, 2022. e-Pub 2022.
4. Cascone T, Spira A, Campelo RG, Kim DW, Hamid O, Soo-Hoo Y, Kumar R, Grenga I, Forde P. NeoCOAST-2: a randomized, open-label, phase 2 study of neoadjuvant durvalumab plus novel immunotherapies and chemotherapy (CT) followed by adjuvant durvalumab plus novel agents, in patients with resectable non-small-cell lung cancer (NSCLC). Cancer Res, 2022. e-Pub 2022.
5. Lazcano, R, Rocha, P, Hernandez, S, Mehta, J, Kang, A, Kannan, K, Lu, W, Powell, S, Khan, K, Parra, E, Zhou, JL, Pandurengan, R, Zhang, JJ, Cascone, T, Behrens, C, Haymaker, C, Wang, LH, Wistuba, I, Kadara, H, Soto, LS. Immune Programs Associated to Tumoral Tertiary Lymphoid Structures at Different Maturation Stages in Early-Stage Lung Adenocarcinoma. Modern Pathology 35, 2022. e-Pub 2022.
6. Lazcano, R, Rocha, P, Hernandez, S, Mehta, J, Kang, A, Kannan, K, Lu, W, Powell, S, Khan, K, Parra, E, Zhou, JL, Pandurengan, R, Zhang, JJ, Cascone, T, Behrens, C, Haymaker, C, Wang, LH, Wistuba, I, Kadara, H, Soto, LS. Immune Programs Associated to Tumoral Tertiary Lymphoid Structures at Different Maturation Stages in Early-Stage Lung Adenocarcinoma. Laboratory Investigation 102:1253-1254, 2022. e-Pub 2022.
7. Cascone T, García-Campelo R, Spicer J, Weder W, Daniel D, Spigel D, Hussein M, Mazieres J, Oliveira J, Yau E, Spira A, Mager R, Hamid O, Cheng LY, Zheng Y, Blando J, McGrath L, Grenga I, Soo-Hoo Y, Kumar R, Forde P. NeoCOAST: open-label, randomized, phase 2, multidrug platform study of neoadjuvant durvalumab alone or combined with novel agents in patients (pts) with resectable, early-stage non-small-cell lung cancer (NSCLC). Cancer Res, 2022. e-Pub 2022.
8. Cascone T, Cascone T, García-Campelo R, Spicer J, Weder W, Daniel D, Spigel D, Hussein M, Mazieres J, Oliveira J, Yau E, Spira A, Mager R, Hamid O, Cheng LY, Zheng Y, Blando J, McGrath L, Grenga I, Soo-Hoo Y, Kumar R, Forde P. NeoCOAST: open-label, randomized, phase 2, multidrug platform study of neoadjuvant durvalumab alone or combined with novel agents in patients (pts) with resectable, early-stage non-small-cell lung cancer (NSCLC). AACR Annual Meeting Plenary Section, 2022. e-Pub 2022.
9. Nassif EF, Chelvanambi M, Chen L, Wu CC, Damania A, Keung EZY, Witt RG, White M, Ajami NJ, Wong MC, Somaiah N, Sepesi B, Basu S, Allison JP, Sharma P, McBride K, Fridman WH, Wargo JA, Cascone T, Roland CL. Identifying gut microbial signatures associated with B cells and tertiary lymphoid structures (TLS) in the tumor microenvironment (TME) in response to immune checkpoint 40(16):2511-251, 2022. e-Pub 2022.
10. Cascone T, Spira A, Campelo RG, Kim DW, Hamid O, Soo-Hoo Y, Kumar R, Grenga I, Forde P. NeoCOAST-2: a randomized, open-label, phase 2 study of neoadjuvant durvalumab plus novel immunotherapies and chemotherapy (CT) followed by adjuvant durvalumab plus novel agents, in patients with resectable non-small-cell lung cancer (NSCLC), 2022. e-Pub 2022.
11. Lazcano, R, Rocha, P, Hernandez, S, Mehta, J, Kang, A, Kannan, K, Lu, W, Powell, S, Khan, K, Parra, E, Zhou, JL, Pandurengan, R, Zhang, JJ, Cascone, T, Behrens, C, Haymaker, C, Wang, LH, Wistuba, I, Kadara, H, Soto, LS. Immune Programs Associated to Tumoral Tertiary Lymphoid Structures at Different Maturation Stages in Early-Stage Lung Adenocarcinoma 102(1):1253-1254, 2022. e-Pub 2022.
12. Lazcano, R, Rocha, P, Hernandez, S, Mehta, J, Kang, A, Kannan, K, Lu, W, Powell, S, Khan, K, Parra, E, Zhou, JL, Pandurengan, R, Zhang, JJ, Cascone, T, Behrens, C, Haymaker, C, Wang, LH, Wistuba, I, Kadara, H, Soto, LS. Immune Programs Associated to Tumoral Tertiary Lymphoid Structures at Different Maturation Stages in Early-Stage Lung Adenocarcinoma 35:1253-1254, 2022. e-Pub 2022.
13. Lee, Y, McGrail, D, Tran, H, Vasquez, ME, Ramos, C, Reuben, A, Vaporciyan, AA, Weissferdt, A, Bernatchez, C, Cascone, T, Wistuba, II, Zhang, JJ, Heymach, J, Negrao, MV, Gibbons, DL, Sepesi, B, Haymaker, CL. Less Circulating biomarkers are associated with recurrence following complete resection of non-small cell lung cancer. Cancer Res 81(13), 2021. e-Pub 2021.
14. Schmidt ST, Lee Y, Leung CH, Federico L, Lin H, Weissferdt A, Pataer A, Dejima H, Francisco-Cruz A, Rojas Alvarez F, Solis LM, Parra ER, Pradhan M, Guo H, William Jr NW, Reuben A, Kadara H, Wistuba II, Zhang J, Swisher SG, Vaporciyan AA, Negrao MV, Bristow CA, Heffernan TP, Bernatchez C, Lee JJ, Heymach JV, Sepesi B, Gibbons DL, Haymaker CL, Cascone T. Integrative immunomics highlight the immunomodulatory impact of neoadjuvant chemotherapy and immune-based treatments in resected non-small-cell lung cancer. Journal for immunotherapy of Cancer 9(2), 2021. e-Pub 2021.
15. Sinjab, A, Han, GC, Treekitkarnmongkol, W, Hara, K, Brennan, P, Dang, MH, Hao, DP, Wang, RP, Dai, EY, Dejima, H, Zhang, JX, Bogatenkova, E, Sanchez-Espiridion, B, Chang, K, Little, DR, Bazzi, S, Tran, L, Krysan, K, Behrens, C, Duose, D, Parra, ER, Raso, MG, Solis, LM, Fukuoka, J, Zhang, JJ, Sepesi, B, Cascone, T, Byers, LA, Gibbons, DL, Chen, JC, Moghaddam, SJ, Ostrin, EJ, Rosen, DG, Heymach, JV, Scheet, P, Dubinett, S, Wistuba, II, Fujimoto, J, Stevenson, CS, Spira, AE, Wang, LH, Kadara, H. Resolving the spatial and cellular architecture of lung adenocarcinoma by multi-region single-cell sequencing. Cancer Res 81(13), 2021. e-Pub 2021.
16. Zhou, N, Sepesi, B, Leung, CH, Lin, HY, William, WN, Weissferdt, A, Pataer, A, Godoy, M, Fossella, FV, Blumenschein, G, Le, XN, Tsao, AS, Zhang, JJ, Hofstetter, WL, Swisher, S, Vaporciyan, AA, Lee, JJ, Gibbons, DL, Heymach, J, Cascone |, T. Less Impact of genomic aberrations and additional therapies on survival outcomes of patients with operable non-small cell lung cancer (NSCLC) from the NEOSTAR study. J Clin Oncol 39(15), 2021. e-Pub 2021.
17. Akhave, N, Schmidt, S, Reuben, A, Cascone, T, Zhang, JH, Li, J, Fujimoto, J, Byers, LA, Sanchez-Espiridion, B, Diao, LX, Wang, J, Federico, L, Forget, MA, McGrail, DJ, Weissferdt, A, Lin, SY, Lee, Y, Behrens, C, Wistuba, II, Futreal, A, Vaporciyan, A, Sepesi, B, Heymach, JV, Bernatchez, C, Haymaker, C, Zhang, JJ, Bristow, CA, Negrao, MV, Gibbons, DL. Integrated multi-platform profiling of early-stage non-small cell lung cancer identifies relationship between disease recurrence and decreased native immune response in treatment-naive resected NSCLC. Cancer Res 81(13), 2021. e-Pub 2021.
18. Schmidt, ST, Akhave, N, Reuben, A, Cascone, T, Zhang, JH, Li, J, Fujimoto, J, Byers, LA, Sanchez-Espiridion, B, Diao, LX, Wang, J, Federico, L, Forget, MA, McGrail, DJ, Weissferdt, A, Lin, SY, Lee, Y, Vokes, N, Behrens, C, Wistuba, II, Futreal, A, Vaporciyan, A, Sepesi, B, Heymach, JV, Bernatchez, C, Haymaker, C, Zhang, JJ, Bristow, CA, Heffernan, TP, Negrao, MV, Gibbons, DL. A shared nearest neighbors approach for integrated, multi-platform networks and its application to the exploration of multiomics data from early-stage non-small cell lung cancers. Mol Can Ther 20(12), 2021. e-Pub 2021.
19. Cascone, T T. Neoadjuvant immunotherapy for operable non-small cell lung cancer: Lessons learned and current challenges. Cancer Res 81(13), 2021. e-Pub 2021.
20. Gordon, M, Roszik, J, Cabanillas, ME, Hu, MIN, Busaidy, NL, Sherman, SI, Dadu, R, Grubbs, EG, Elamin, Y, Cascone, T, Byers, LA, Blumenschein, GR, Fossella, FV, Naing, A, Hong, DS, Heymach, J, Meric-Bernstam, F, Subbiah, V. Prognostic factors in RET dependent cancers treated with RET inhibitors in early phase clinical trials. J Clin Oncol 39(15), 2021. e-Pub 2021.
21. Frank, M, Shah, P, Forget, MA, Federico, L, Jiang, PX, Khairullah, R, Wistuba, I, Chow, CW, Long, Y, Fujimoto, J, Lin, SY, Maitra, A, Negrao, M, Mitchell, K, Weissferdt, A, Vaporciyan, A, Cascone, T, Roth, J, Zhang, JJ, Sepesi, B, Gibbons, Heymach, J, Haymaker, C, McGrail, D, Bernatchez, C, Reuben, A. A. COMBINED IL-2, AGONISTIC CD3 AND 4-1BB STIMULATION PRESERVE CLONOTYPE HIERARCHY IN PROPAGATED NON-SMALL CELL LUNG CANCER TUMOR-INFILTRATING LYMPHOCYTES. Immunotherapy of Cancer 9:a186, 2021. e-Pub 2021.
22. Schmidt ST, Lee Y, Leung CH, Federico L, Lin H, Weissferdt A, Pataer A, Dejima H, Francisco-Cruz A, Rojas Alvarez F, Solis LM, Parra ER, Pradhan M, Guo H, William Jr NW, Reuben A, Kadara H, Wistuba II, Zhang J, Swisher SG, Vaporciyan AA, Negrao MV, Bristow CA, Heffernan TP, Bernatchez C, Lee JJ, Heymach JV, Sepesi B, Gibbons DL, Haymaker CL, Cascone T. Integrative immunomics highlight the immunomodulatory impact of neoadjuvant chemotherapy and immune-based treatments in resected non-small-cell lung cancer 9(2), 2021. e-Pub 2021.
23. Gordon, M, Roszik, J, Cabanillas, ME, Hu, MIN, Busaidy, NL, Sherman, SI, Dadu, R, Grubbs, EG, Elamin, Y, Cascone, T, Byers, LA, Blumenschein, GR, Fossella, FV, Naing, A, Hong, DS, Heymach, J, Meric-Bernstam, F, Subbiah, V. Prognostic factors in RET dependent cancers treated with RET inhibitors in early phase clinical trials 39(15), 2021. e-Pub 2021.
24. Sinjab, A, Han, GC, Treekitkarnmongkol, W, Hara, K, Brennan, P, Dang, MH, Hao, DP, Wang, RP, Dai, EY, Dejima, H, Zhang, JX, Bogatenkova, E, Sanchez-Espiridion, B, Chang, K, Little, DR, Bazzi, S, Tran, L, Krysan, K, Behrens, C, Duose, D, Parra, ER, Raso, MG, Solis, LM, Fukuoka, J, Zhang, JJ, Sepesi, B, Cascone, T, Byers, LA, Gibbons, DL, Chen, JC, Moghaddam, SJ, Ostrin, EJ, Rosen, DG, Heymach, JV, Scheet, P, Dubinett, S, Wistuba, II, Fujimoto, J, Stevenson, CS, Spira, AE, Wang, LH, Kadara, H. Resolving the spatial and cellular architecture of lung adenocarcinoma by multi-region single-cell sequencing 81(13), 2021. e-Pub 2021.
25. Patel, S, Herynk, M, Cascone, T, Saigal, B, Nilsson, M, Tran, H, Ramachandran, S, Minna, J, Wistuba, I, Heymach, J. Estrogen Promotes Resistance to Bevacizumab Treatment in Non-Small Cell Lung Cancer (NSCLC) Xenograft Models. J Thorac Oncol 16(3):s564, 2021. e-Pub 2021.
26. Akhave, N, Schmidt, S, Reuben, A, Cascone, T, Zhang, JH, Li, J, Fujimoto, J, Byers, LA, Sanchez-Espiridion, B, Diao, LX, Wang, J, Federico, L, Forget, MA, McGrail, DJ, Weissferdt, A, Lin, SY, Lee, Y, Behrens, C, Wistuba, II, Futreal, A, Vaporciyan, A, Sepesi, B, Heymach, JV, Bernatchez, C, Haymaker, C, Zhang, JJ, Bristow, CA, Negrao, MV, Gibbons, DL. . Integrated multi-platform profiling of early-stage non-small cell lung cancer identifies relationship between disease recurrence and decreased native immune response in treatment-naive resected NSCLC 81(13), 2021. e-Pub 2021.
27. Rocha, P, Zhang, J, Laza-Briviesca, R, Cruz-Bermudez, A, Yoshimura, K, Behrens, C, Pataer, A, Parra, ER, Haymaker, C, Fujimoto, J, Swisher, SG, Heymach, JV, Gibbons, DL, Lee, JJ, Sepesi, B, Cascone, T\, Solis, LM, Provencio, M, Kadara, H, Wistuba, II. Distinct immune gene programs associated with host tumor immunity, neoadjuvant chemotherapy and chemoimmunotherapy in resectable NSCLC. Annals Oncol 32:s1377, 2021. e-Pub 2021.
28. Yoshimura, K, Behrens, C, Pataer, A, Parra, ER, Haymaker, C, Fujimoto, J, Swisher, SG, Heymach, JV, Gibbons, DL, Lee, JJ, Sepesi, B, Cascone, T, Solis, LM, Provencio, M, Kadara, H, Wistuba, II. Distinct immune gene programs associated with host tumor immunity, neoadjuvant chemotherapy and chemoimmunotherapy in resectable NSCLC 32:S1377-S1377, 2021. e-Pub 2021.
29. Schmidt, ST, Akhave, N, Reuben, A, Cascone, T, Zhang, JH, Li, J, Fujimoto, J, Byers, LA, Sanchez-Espiridion, B, Diao, LX, Wang, J, Federico, L, Forget, MA, McGrail, DJ, Weissferdt, A, Lin, SY, Lee, Y, Vokes, N, Behrens, C, Wistuba, II, Futreal, A, Vaporciyan, A, Sepesi, B, Heymach, JV, Bernatchez, C, Haymaker, C, Zhang, JJ, Bristow, CA, Heffernan, TP, Negrao, MV, Gibbons, DL. A shared nearest neighbors approach for integrated, multi-platform networks and its application to the exploration of multiomics data from early-stage non-small cell lung cancers 20(12), 2021. e-Pub 2021.
30. Schumann, C, Cascone, T, Provencio, M, Sepesi, B, Lu, S, Aanur, N, Li, S, Spicer, J. CheckMate 77 T: A phase 3 trial of neoadjuvant nivolumab (NIVO). Pneumologie 75:s16, 2021. e-Pub 2021.
31. Cascone T. Neoadjuvant immunotherapy for operable non-small cell lung cancer: Lessons learned and current challenges 81(13), 2021. e-Pub 2021.
32. Frank, M, Shah, P, Forget, MA, Federico, L, Jiang, PX, Khairullah, R, Wistuba, I, Chow, CW, Long, Y, Fujimoto, J, Lin, SY, Maitra, A, Negrao, M, Mitchell, K, Weissferdt, A, Vaporciyan, A, Cascone, T, Roth, J, Zhang, JJ, Sepesi, B, Gibbons, Heymach, J, Haymaker, C, McGrail, D, Bernatchez, C, Reuben, A. Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated Non-small cell lung cancer tumor-infiltrating lymphocytes 9:A186-A186, 2021. e-Pub 2021.
33. Lee, Y, McGrail, D, Tran, H, Vasquez, ME, Ramos, C, Reuben, A, Vaporciyan, AA, Weissferdt, A, Bernatchez, C, Cascone, T, Wistuba, II, Zhang, JJ, Heymach, J, Negrao, MV, Gibbons, DL, Sepesi, B, Haymaker, CL. Less Circulating biomarkers are associated with recurrence following complete resection of non-small cell lung cancer 81(13), 2021. e-Pub 2021.
34. Fossella, FV, Blumenschein, G, Le, XN, Tsao, AS, Zhang, JJ, Hofstetter, WL, Swisher, S, Vaporciyan, AA, Lee, JJ, Gibbons, DL, Heymach, J, Cascone, T. Less Impact of genomic aberrations and additional therapies on survival outcomes of patients with operable non-small cell lung cancer (NSCLC) from the NEOSTAR study 39(15), 2021. e-Pub 2021.
35. Li, J, Wang, Y, Tang, C, Welsh, JW, Guha-Thakurta, N, Carter, BW, Wefel, JS, Ghia, AJ, Yeboa, D, McAleer, MF, Chung, C, Woodhouse, KD, Elamin, Y, Le, XN, |BCascone, T\\b, Negrao, MV, Skoulidis, F, Ferrarotto, R, Heymach, J, Altan, M. Concurrent nivolumab and ipilimumab with brain stereotactic radiosurgery for brain metastases from non-small cell lung cancer: A phase I trial 38(15), 2020. e-Pub 2020.
36. Li, J, Wang, Y, Tang, C, Welsh, JW, Guha-Thakurta, N, Carter, BW, Wefel, JS, Ghia, AJ, Yeboa, DN, McAleer, MF, Chung, C, Woodhouse, KD, Elamin, Y, Le, X, Cascone, T, Negrao, MV, Skoulidis, F, Ferrarotto, R, Heymach, J, Altan, M. Concurrent Nivolumab And Ipilimumab With Brain Stereotactic Radiosurgery For Brain Metastases From Non-Small Cell Lung Cancer: A Phase I Trial. International J Rad Oncol Biol Physics 108(3):e744, 2020. e-Pub 2020.
37. Sepesi, B, Corsini, E, Weissferdt, A, Pataer, A, Altan, M, Antonoff, M, Blumenschein, G, Elamin, Y, Fossella, F, Glisson, B, Hofstetter, W, Kurie, J, Le, XN, Leung, CH, Lin, H, Lu, C, Mehran, R, Mott, F, Rice, D, Roth, J, Skoulidis, F, Swisher, S, Tsao, A, Vaporciyan, A, Walsh, G, Zhang, JJ, Gibbons, D, Heymach, J, Cascone, T. COMBINED NEOADJUVANT CHEMO-IMMUNOTHERAPY THERAPY ACHIEVES SUPERIOR DOWNSTAGING OF RESECTABLE NON-SMALL CELL LUNG CANCER AS COMPARED TO CHEMOTHERAPY, MONO OR DUAL IMMUNOTHERAPY 8:a169, 2020. e-Pub 2020.
38. Treekitkarnmongkol, W, Finnicum, C, Sinjab, A, Hassane, M, Davis, C, Davies, GE, Hoffman, KL, Fujimoto, J, McAllister, F, Sepesi, B, |BCascone, T||B, Jenq, RR, Petrosino, J, Ehli, E, Moghaddam, SJ, Kadara, H. Evolution of the gut Amicrobiome during the pathogenesis of smoking-associated Kras-mutant lung cancer. Cancer Res 80(16), 2020. e-Pub 2020.
39. Elamin, Y, Gandhi, S, Antonoff, M, Mott, F, Gibbons, DL, Le, XN, Negrao, MV, Sepesi, B, Karam, JA, |BCascone, T||B, Wang, LH, Blumenschein, G, Glisson, BS, Tsao, AS, Heymach, J. BRIGHTSTAR: A pilot trial of local consolidative therapy (LCT) with brigatinib in tyrosine kinase inhibitor (TKI)-naive ALK-rearranged advanced NSCLC. J Clin Oncol 38(15), 2020. e-Pub 2020.
40. |BCascone, T||B, Provencio, M, Sepesi, B, Lu, S, Aanur, N, Li, SN, Spicer, J. Checkmate 77T: A phase III trial of neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) followed by adjuvant nivo in resectable early-stage NSCLC. J Clin Oncol 38(15), 2020. e-Pub 2020.
41. Patel, S, Herynk, M, Cascone, T, Saigal, B, Nilsson, M, Tran, H, Ramachandran, S, Minna, J, Wistuba, I, Heymach, J. Estrogen Promotes Resistance to Bevacizumab Treatment in Non-Small Cell Lung Cancer (NSCLC) Xenograft Models 16(3):S564-S565, 2020. e-Pub 2020.
42. Li, J, Wang, Y, Tang, C, Welsh, JW, Guha-Thakurta, N, Carter, BW, Wefel, JS, Ghia, AJ, Yeboa, D, McAleer, MF, Chung, C, Woodhouse, KD, Elamin, Y, Le, XN, Cascone, T, Negrao, MV, Skoulidis, F, Ferrarotto, R, Heymach, J, Altan, M. Concurrent nivolumab and ipilimumab with brain stereotactic radiosurgery for brain metastases from non-small cell lung cancer: A phase I trial 38(15), 2020. e-Pub 2020.
43. Cascone, T, Provencio, M, Sepesi, B, Lu, S, Aanur, N, Li, SN, Spicer, J. Checkmate 77T: A phase III trial of neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) followed by adjuvant nivo in resectable early-stage NSCLC 38(15), 2020. e-Pub 2020.
44. Treekitkarnmongkol, W, Finnicum, C, Sinjab, A, Hassane, M, Davis, C, Davies, GE, Hoffman, KL, Fujimoto, J, McAllister, F, Sepesi, B, Cascone, T, Jenq, RR, Petrosino, J, Ehli, E, Moghaddam, SJ, Kadara, H. Evolution of the gut Amicrobiome during the pathogenesis of smoking-associated Kras-mutant lung cancer 80(16), 2020. e-Pub 2020.
45. Elamin, Y, Gandhi, S, Antonoff, M, Mott, F, Gibbons, DL, Le, XN, Negrao, MV, Sepesi, B, Karam, JA, Cascone, T, Wang, LH, Blumenschein, G, Glisson, BS, Tsao, AS, Heymach, J. BRIGHTSTAR: A pilot trial of local consolidative therapy (LCT) with brigatinib in tyrosine kinase inhibitor (TKI)-naive ALK-rearranged advanced NSCLC 38(15), 2020. e-Pub 2020.
46. Sepesi, B, Corsini, E, Weissferdt, A, Pataer, A, Altan, M, Antonoff, M, Blumenschein, G, Elamin, Y, Fossella, F, Glisson, B, Hofstetter, W, Kurie, J, Le, XN, Leung, CH, Lin, H, Lu, C, Mehran, R, Mott, F, Rice, D, Roth, J, Skoulidis, F, Swisher, S, Tsao, A, Vaporciyan, A, Walsh, G, Zhang, JJ, Gibbons, D, Heymach, J, Cascone, T. Combined neoadjuvant chemoimmunotherapy achieves superior downstaging of resectable non-small cell lung cancer as compared to chemotherapy, mono or dual immunotherapy 8(3):A169-A169, 2020. e-Pub 2020.
47. Li, J, Wang, Y, Tang, C, Welsh, JW, Guha-Thakurta, N, Carter, BW, Wefel, JS, Ghia, AJ, Yeboa, DN, McAleer, MF, Chung, C, Woodhouse, KD, Elamin, Y, Le, X, Cascone, T, Negrao, MV, Skoulidis, F, Ferrarotto, R, Heymach, J, Altan, M. Concurrent Nivolumab And Ipilimumab With Brain Stereotactic Radiosurgery For Brain Metastases From Non-Small Cell Lung Cancer: A Phase I Trial 108(3):E744-E744, 2020. e-Pub 2020.
48. Cascone T, William WN, Weissferdt A, Lin HY, Leung CH, Carter BW, Fossella FV, Mott F, Papadimitrakopoulou V, Blumenschein GR, Jr, Le X, Federico L, Parra Cuentas ER, Bernatchez C, Wistuba II, Vaporciyan AA, Gibbons DL, Swisher S, Heymach J, Sepesi B. Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study. American Sociey of Clinical Oncology 2019, 2019. e-Pub 2019.
49. Cascone, T, William, WN, Weissferdt, A, Lin, HY, Leung, CH, Carter, BW, Fossella, FV, Mott, F, Papadimitrakopoulou, V, Blumenschein, G, Le, X, Federico, L, Cuentas, ERP, Bernatchez, C, Wistuba, II, Vaporciyan, AA, Gibbons, DL, Swisher, S, Heymach, J, Sepesi, B. Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study. J Clin Oncol 37(15), 2019. e-Pub 2019.
50. Reuben A, Zhang J, Lin HY, Little L, Gumbs C, Tran HT, Wang L, Haymaker CL, Mehran RJ, Rice DC, Walsh GL, Lee J, Wistuba II, Swisher S, Vaporciyan AA, Futreal A, Sepesi B, Heymach J, Gibbons DL, Cascone T, Group NS. T cell repertoire analysis of non-small cell lung cancer patients treated with neoadjuvant nivolumab alone or in combination with ipilimumab (NEOSTAR trail). J Clin Oncol 37(15), 2019. e-Pub 2019.
51. Mitchell KG, Diao L, Tran HT, Negrao MV, Karpinets T, Wang J, Parra Cuentas ER, Corsini EM, Reuben A, Federico L, Bernatchez C, Vaporciyan AA, Swisher S, Cascone T, Wistuba II, Heymach J, Zhang J, Gibbons DL, Haymaker CL, Sepesi B. Association of relative neutrophilia with a distinct immunoinihibitory. Clin Oncol, 2019. e-Pub 2019.
52. Sepsi B, Cascone T, William WN, Lin H, Leung C, Weissferdt A, Walsh GL, Rice D, Roth J, Mehran RJ, Hofstetter WL, Antonoff M, Fossella F, Mott FE, Le X, Skoulidis F, Zhang J, Byers LA, Lam V, Glisson B, Kurie J, Blumenschein G, Tsao A, Lu C, Altan M, Elamin Y, Gibbons DL, Papadimitrakopoulou VA, Lee J, Heymach JV, Vaporciyan AA, Swisher S. Surgical outcomes following neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Non-Small Cell Lung Cancer - NEOSTAR Study. J Thorac Oncol, 2019. e-Pub 2019.
53. Chen, LM, Diao, LX, Yi, XH, Rodriguez, BL, Li, YL, Villalobos, P, Cascone, T, Liu, X, Tan, L, Lorenzi, P, Fradette, J, Peng, D, Skoulidis, F, Fan, YH, Rodriguez-Canales, J, Papadimitrakopoulou, V, Dmitrovsky, E, Byers, LA, Wang, J, Wistuba, I, Heymach, J, Gibbons, D. Tackling the tumor microenvironment with CD38 blockade to enhance cancer immunotherapy. Cancer Immunol Res 7(2), 2019. e-Pub 2019.
54. Hassane, M, Treekitkarnmongkol, W, McDowell, TL, Sivakumar, S, Lang, WH, Ochieng, JK, Nunomura-Nakamura, S, Finnicum, C, Davis, C, Davies, GE, Fukuoka, J, Cascone, T, McAllister, F, Wistuba, II, Ehli, E, Moghaddam, SJ, Scheet, P, Fujimoto, J, Kadara, H. Host lipocalin 2 protects against Kras mutant lung cancer development by maintaining an anti-tumor immune contexture. Cancer Research 79(13), 2019. e-Pub 2019.
55. Negrao, MV, Karpinets, T, Li, J, Reuben, A, Haymaker, C, Mitchell, KG, Fujimoto, J, Chow, CW, Parra, ER, Federico, L, Zhang, JH, Vaporciyan, AA, Bernatchez, C, Cascone, T, Sepesi, B, Wistuba, II, Heymach, JV, Zhang, JJ, Gibbons, DL. Immunogenomic profiling identifies a subgroup of squamous cell lung cancers with immunosuppressed tumor microenvironment and correlates TGF-beta and Wnt/beta-catenin signaling as predictive of low PD-L1 expression. Cancer Res 79(13), 2019. e-Pub 2019.
56. Campelo, RG, Forde, P, Weder, W, Spicer, J, He, P, Hamid, O, Martinez, P, Cascone, T. NeoCOAST: Neoadjuvant Durvalumab Alone or with Novel Agents for Resectable, Early-Stage (I-IIIA) Non-Small Cell Lung Cancer 14(10):S719-S719, 2019. e-Pub 2019.
57. Mitchell, KG, Diao, L, Tran, HT, Negrao, MV, Karpinets, T, Wang, J, Cuentas, ERP, Corsini, EM, Reuben, A, Federico, L, Bernatchez, C, Vaporciyan, AA, Swisher, S, Cascone, T, Wistuba, II, Heymach, J, Zhang, JJ, Gibbons, DL, Haymaker, CL, Sepesi, B. Association of relative neutrophilia with a distinct immunoinhibitory milieu in non-small cell lung cancer 37(15), 2019. e-Pub 2019.
58. Negrao, MV, Karpinets, T, Li, J, Reuben, A, Haymaker, C, Mitchell, KG, Fujimoto, J, Chow, CW, Parra, ER, Federico, L, Zhang, JH, Vaporciyan, AA, Bernatchez, C, Cascone, T, Sepesi, B, Wistuba, II, Heymach, JV, Zhang, JJ, Gibbons, DL. Immunogenomic profiling identifies a subgroup of squamous cell lung cancers with immunosuppressed tumor microenvironment and correlates TGF-beta and Wnt/beta-catenin signaling as predictive of low PD-L1 expression 79(13), 2019. e-Pub 2019.
59. Campelo, RG, Forde, P, Weder, W, Spicer, J, He, P, Hamid, O, Martinez, P, Cascone |, ||B T. Neoadjuvant Durvalumab Alone or with Novel Agents for Resectable, Early-Stage (I-IIIA) Non-Small Cell Lung Cancer. J Thorac Oncol 14(10):S713, 2019. e-Pub 2019.
60. Chen, LM, Diao, LX, Yi, XH, Rodriguez, BL, Li, YL, Villalobos, P, Cascone, T, Liu, X, Tan, L, Lorenzi, P, Fradette, J, Peng, D, Skoulidis, F, Fan, YH, Rodriguez-Canales, J, Papadimitrakopoulou, V, Dmitrovsky, E, Byers, LA, Wang, J, Wistuba, I, Heymach, J, Gibbons, D. Tackling the tumor microenvironment with CD38 blockade to enhance cancer immunotherapy 7(2), 2019. e-Pub 2019.
61. Gaudreau P, Ajami N, Sepesi B, Karpinets T, Reuben A, Wong M, Parra E, Federico L, Gopalakrishnan V, Mitchell K, Negrao M, Spencer C, Vaporciyan A, Weissferdt A, Haymaker C, Tran H, Bernatchez C, Landry L, Roarty E, Cascone T, Heymach J, Zhang J, Wistuba I, Zhang J, Wargo J, Gibbons D. Depicting the Intra-Tumoral Viral and Microbial Landscape of Localized NSCLC Using Standard Next Generation Sequencing Data 14(10):S443, 2019. e-Pub 2019.
62. Sepesi, B, Godoy, M, William, W, Vaporciyan, A, Lin, H, Leung, C, Lee, J, Mitchell, K, Weissferdt, A, Le, X, Lam, V, Fossella, F, Swisher, S, Heymach, J, Cascone, T T. Nodal Immune Flare (NIF) Following Neoadjuvant Anti-PD-1 and Anti-CTLA-4 Therapy in Non-Small Cell Lung Cancer. J Thorac Oncol 14(10):s745, 2019. e-Pub 2019.
63. Gaudreau, P, Negrao, M, Mitchell, K, Corsini, E, Karpinets, T, Wang, Q, Diao, L, Wang, J, Federico, L, Parra, E, Li, J, Behrens, C, Correa, A, Gomez, D, Vaporciyan, A, Weissferdt, A, Tran, H, Roarty, E, Wistuba, I, Reuben, A, Haymaker, C, Bernatchez, C, Cascone, T, Heymach, J, Sepesi, B, Zhang, J, Gibbons, D. Neoadjuvant Chemotherapy Is Associated with Immunogenic Cell Death and Increased T Cell Infiltration in Early-Stage NSCLC. J Thorac Oncol 14(10):S715, 2019. e-Pub 2019.
64. Reuben, A, Zhang, JJ, Lin, HY, Little, L, Gumbs, C, Tran, HT, Wang, LH, Haymaker, CL, Mehran, RJ, Rice, DC, Walsh, GL, Lee, JJ, Wistuba, II, Swisher, S, Vaporciyan, AA, Futreal, A, Sepesi, B, Heymach, J, Gibbons, DL, Cascone, T. T cell repertoire analysis of non-small cell lung cancer patients treated with neoadjuvant nivolumab alone or in combination with ipilimumab (NEOSTAR trial) 37(19), 2019. e-Pub 2019.
65. Reuben, A, Zhang, J, Gittelman, R, Chiou, S, Li, J, Fujimoto, J, Behrens, C, Kheradmand, F, Chow, C, Bernatchez, C, Eterovic, AK, Benzeno, S, Vignali, M, Wu, XXF, Ye, Y, Cascone, T, Herbst, R, Swisher, S, Kadara, H, Moran, C, Zhang, J, Scheet, P, Vaporciyan, A, Sepesi, B, Gibbons, D, Robins, H, Hwu, P, Heymach, J, Sharma, P, Allison, J, Lee, J, Davis, M, Wistuba, I, Futreal, PA, Zhang, J. Increased Frequency of Bystander T Cells in the Lungs Is Associated with Recurrence in Localized Non-Small Cell Lung Cancer. J Thorac Oncol 14(10):S293, 2019. e-Pub 2019.
66. Sepesi, B, Cascone, T, William, W, Lin, H, Leung, C, Weissferdt, A, Walsh, G, Rice, D, Roth, J, Mehran, R, Hofstetter, W, Antonoff, M, Fossella, F, Mott, F, Le, X, Skoulidis, F, Zhang, J, Byers, L, Lam, V, Glisson, B, Kurie, J, Blumenschein, G, Tsao, A, Lu, C, Altan, M, Elamin, Y, Gibbons, D, Papadimitrakopoulou, V, Lee, J, Heymach, J, Vaporciyan, A, Swisher, S. Surgical Outcomes Following Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Non-Small Cell Lung Cancer - NEOSTAR Study 14(10):S241-S242, 2019. e-Pub 2019.
67. Gaudreau, P, Negrao, M, Mitchell, K, Corsini, E, Karpinets, T, Wang, Q, Diao, L, Wang, J, Federico, L, Parra, E, Li, J, Behrens, C, Correa, A, Gomez, D, Vaporciyan, A, Weissferdt, A, Tran, H, Roarty, E, Wistuba, I, Reuben, A, Haymaker, C, Bernatchez, C, Cascone, T, Heymach, J, Sepesi, B, Zhang, J, Gibbons, D. Neoadjuvant Chemotherapy Is Associated with Immunogenic Cell Death and Increased T Cell Infiltration in Early-Stage NSCLC 14(10):S715-S715, 2019. e-Pub 2019.
68. Hassane, M, Treekitkarnmongkol, W, McDowell, TL, Sivakumar, S, Lang, WH, Ochieng, JK, Nunomura-Nakamura, S, Finnicum, C, Davis, C, Davies, GE, Fukuoka, J, Cascone, T, McAllister, F, Wistuba, II, Ehli, E, Moghaddam, SJ, Scheet, P, Fujimoto, J, Kadara, H. Host lipocalin 2 protects against Kras mutant lung cancer development by maintaining an anti-tumor immune contexture 79(13), 2019. e-Pub 2019.
69. Cascone T, William WN, Weissferdt A, Lin HY, Leung CH, Carter BW, Fossella FV, Mott F, Papadimitrakopoulou V, Blumenschein GR, Jr, Le X, Federico L, Parra Cuentas ER, Bernatchez C, Wistuba II, Vaporciyan AA, Gibbons DL, Swisher S, Heymach J, Sepesi B. Neoadjuvant nivolumab (N) or nivlumab plus ipilimuman (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study. Ann Oncol 29, 2018. e-Pub 2018.
70. Cascone T, Boris Sepesi B Lin H, Neda Kalhor N, Zhang J, Fossella FV, Anne Tsao A, Lam VK, Lu C, Mott FE, Simon G, Antonoff M, Mehran RJ, Rice DC, Vaporciyan A, Godoy M, Lee JJ, Swisher SG, William Jr WN, Heymach JV. A phase I study of neoadjuvant cisplatin (C), docetaxel (D) and nintedanib (N) for resectable non-small cell lung cancer (NSCLC). J Clin Oncol, 2018. e-Pub 2018.
71. Weissferdt A, Sepesi B, Pataer A, Kalhor N, Moran CA, William WN, Le X, Glisson B, Skoulidis F, Blumenschein G, Zhang J, Altan M, Rice D, Mehran R, Lee JJ, Vaporciyan A, Gibbons DL, Swisher SG, Heymach JV, Cascone T. Pathologic assessment following neoadjuvant immunotherapy or chemotherapy demonstrates similar patterns in non-small cell lung cancer (NSCLC). Ann Oncol 29:680, 2018. e-Pub 2018.
72. Weissferdt, A, Cascone, T, Pataer, A, Kalhor, N, Moran, C, Antonoff, MB, Walsh, G, Bernatchez, C, Gibbons, D, Wistuba, I, Roth, J, Zhang, J, Roarty, E, Landry, LCADL, Vaporciyan, A, Heymach, JV, Swisher, S, Sepesi, B. Histopathologic Parameters Define Features of Treatment Response to Neoadjuvant Chemotherapy in Non-Small Cell Lung Cancer. J Thorac Oncol 13(10):a958, 2018. e-Pub 2018.
73. Cascone T, Hamdi H, Fahao Zhang F, Poteete A, Li L, Hudgens C, Williams L, Wu Q, Gudikote J, Peng W, Hwu P, Wang J, Tetzlaff M, William Jr WN, Heymach JV. Superior efficacy of neoadjuvant compared to adjuvant immune checkpoint blockade in non-small cell lung cancer. Cancer Res 78(13), 2018. e-Pub 2018.
74. Peng, WY, Cascone |, T||B, McKenzie, J, Mbofung, R, Punt, S, Wang, Z, Xu, CY, Williams, L, Wang, ZQ, Bristow, C, Carugo, A, Peoples, M, Li, LR, Karpinets, T, Huang, L, Malu, S, Creasy, C, Leahey, S, Chen, J, Bernatchez, C, Gopal, V, Heffernan, T, Hu, JH, Wang, J, Amaria, R, Wistuba, I, Woodman, S, Roszik, J, Davis, E, Davies, M, Heymach, J, Hwu, P. The metabolic basis of resistance to Adoptive T Cell Therapy (ACT) in patients with solid tumors. J Immunol 200(1), 2018. e-Pub 2018.
75. Federico, L, Haymaker, CL, Forget, MA, Ravelli, A, Bhatta, A, Karpinets, T, Zhang, R, Weissferdt, A, Fang, BL, Zhang, JJ, Cascone, T, Vaporciyan, AA, Futreal, A, Wistuba, II, Sepesi, B, Heymach, J, Gibbons, DL, Bernatchez, C. A preclinical study of tumor-infiltrating lymphocytes in NSCLC. J Clin Oncol 36(5), 2018. e-Pub 2018.
76. Subbiah, V, Cascone, T||B, Hess, KR, Subbiah, IM, Nelson, S, Morikawa, N, Nilsson, MB, Bhatt, T, Ali, S, William, WN, Raymond, VM, Lanman, RB, Carbone, DP, Salgia, R, Owonikoko, TK, Simon, GR, Meric-Bernstam, F, Doebele, RC, Heymach, J. Multi-kinase RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with RET rearranged non-small cell lung cancer. J Clin Oncol 36(15), 2018. e-Pub 2018.
77. Cascone, T, William, WN, Weissferdt, A, Lin, HY, Leung, CH, Carter, BW, Fossella, FV, Mott, F, Papadimitrakopoulou, V, Blumenschein, G, Le, X, Federico, L, Cuentas, ERP, Bernatchez, C, Wistuba, II, Vaporciyan, AA, Gibbons, DL, Swisher, S, Heymach, J, Sepesi, B. Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study 37(15), 2018. e-Pub 2018.
78. Cascone T, Hamdi H, Fahao Zhang F, Poteete A, Li L, Hudgens C, Williams L, Wu Q, Gudikote J, Peng W, Hwu P, Wang J, Tetzlaff M, William Jr WN, Heymach JV. Superior efficacy of neoadjuvant compared to adjuvant immune checkpoint blockade in non-small cell lung cancer 78(13), 2018. e-Pub 2018.
79. Peng, WY, Cascone, T, McKenzie, J, Mbofung, R, Punt, S, Wang, Z, Xu, CY, Williams, L, Wang, ZQ, Bristow, C, Carugo, A, Peoples, M, Li, LR, Karpinets, T, Huang, L, Malu, S, Creasy, C, Leahey, S, Chen, J, Bernatchez, C, Gopal, V, Heffernan, T, Hu, JH, Wang, J, Amaria, R, Wistuba, I, Woodman, S, Roszik, J, Davis, E, Davies, M, Heymach, J, Hwu, P. The metabolic basis of resistance to Adoptive T Cell Therapy (ACT) in patients with solid tumors 200(1), 2018. e-Pub 2018.
80. Sepesi, B, Federico, L, Mitchell, K, Parra, E, Cruz, AF, Ravelli, A, Haymaker, C, Karpinets, T, Cascone, T, Weissferdt, A, Antonoff, MB, Walsh, G, Bernatchez, C, Roth, J, Zhang, J, Roarty, E, Landry, LCADL, Vaporciyan, A, Swisher, S, Heymach, J, Wistuba, I, Gibbons, D. PD-L1 Expression is Predominant in CD68+Tumor-Associated Macrophages in Stage I-III Non-Small Cell Lung Cancers 13(10):S516-S516, 2018. e-Pub 2018.
81. Cascone T, William WN, Weissferdt A, Lin HY, Leung CH, Carter BW, Fossella FV, Mott F, Papadimitrakopoulou V, Blumenschein GR, Jr, Le X, Federico L, Parra Cuentas ER, Bernatchez C, Wistuba II, Vaporciyan AA, Gibbons DL, Swisher S, Heymach J, Sepesi B. Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study 29(8), 2018. e-Pub 2018.
82. Weissferdt, A, Cascone, T, Pataer, A, Kalhor, N, Moran, C, Antonoff, MB, Walsh, G, Bernatchez, C, Gibbons, D, Wistuba, I, Roth, J, Zhang, J, Roarty, E, Landry, LCADL, Vaporciyan, A, Heymach, JV, Swisher, S, Sepesi, B. Histopathologic Parameters Define Features of Treatment Response to Neoadjuvant Chemotherapy in Non-Small Cell Lung 13(10):S958-S958, 2018. e-Pub 2018.
83. Sepesi, B, Federico, L, Mitchell, K, Parra, E, Cruz, AF, Ravelli, A, Haymaker, C, Karpinets, T, |BCascone, T||B, Weissferdt, A, Antonoff, MB, Walsh, G, Bernatchez, C, Roth, J, Zhang, J, Roarty, E, Landry, LCADL, Vaporciyan, A, Swisher, S, Heymach, J, Wistuba, I, Gibbons, D. PD-L1 Expression is Predominant in CD68+Tumor-Associated Macrophages in Stage I-III Non-Small Cell Lung Cancers. J Thorac Oncol 13(10):S516, 2018. e-Pub 2018.
84. Subbiah, V, Cascone, T, Hess, KR, Subbiah, IM, Nelson, S, Morikawa, N, Nilsson, MB, Bhatt, T, Ali, S, William, WN, Raymond, VM, Lanman, RB, Carbone, DP, Salgia, R, Owonikoko, TK, Simon, GR, Meric-Bernstam, F, Doebele, RC, Heymach, J. Multi-kinase RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with RET rearranged non-small cell lung cancer 36(15), 2018. e-Pub 2018.
85. Weissferdt A, Sepesi B, Pataer A, Kalhor N, Moran CA, William WN, Le X, Glisson B, Skoulidis F, Blumenschein G, Zhang J, Altan M, Rice D, Mehran R, Lee JJ, Vaporciyan A, Gibbons DL, Swisher SG, Heymach JV, Cascone T. Pathologic assessment following neoadjuvant immunotherapy or chemotherapy demonstrates similar patterns in non-small cell lung cancer (NSCLC) 29(8):680-680, 2018. e-Pub 2018.
86. Federico, L, Haymaker, CL, Forget, MA, Ravelli, A, Bhatta, A, Karpinets, T, Zhang, R, Weissferdt, A, Fang, BL, Zhang, JJ, Cascone, T, Vaporciyan, AA, Futreal, A, Wistuba, II, Sepesi, B, Heymach, J, Gibbons, DL, Bernatchez, C. A preclinical study of tumor-infiltrating lymphocytes in NSCLC 36(5), 2018. e-Pub 2018.
87. Cascone, T, Sepesi, B, Lin, HY, Kalhor, N, Zhang, JJ, Fossella, FV, Tsao, AS, Lam, VK, Lu, C, Mott, F, Simon, GR, Antonoff, M, Mehran, RJ, Rice, DC, Vaporciyan, AA, Godoy, M, Lee, JJ, Swisher, S, William, WN, Heymach, J. A phase I study of neoadjuvant cisplatin (C), docetaxel (D) and nintedanib (N) for resectable non-small cell lung cancer (NSCLC) 36(15), 2018. e-Pub 2018.
88. Reuben, A, Gittelman, R, Zhang, J, Chen, R, Quek, K, Vence, L, Fernandez-Cubelo, I, Behrens, C, Gao, J, Yusko, E, Emerson, R, Benzeno, S, Vignali, M, Tipton, C, Jalali, A, Lee, W, Wu, C, Li, J, Wu, X, Ye, Y, Eterovic, A, Little, L, Gumbs, C, Bernatchez, C, Haymaker, C, Forget, M, Federico, L, Cascone, T, Robins, H, Roarty, E, Rodriguez, J, Parra, E, Wargo, J, Allison, J, Sharma, P, Zhang, J, Lee, J, Sepesi, B, Swisher, S, Gibbons, D, Heymach, J, Futreal, A, Wistuba, I, Zhang, J. Immune, Molecular and T Cell Repertoire Landscape of 235 Resected Non-Small Cell Lung Cancers and Paired Normal Lung Tissues. Journal for Immunotherapy of Cancer 5, 2017. e-Pub 2017.
89. Cascone T, McKenzie JA, Mbofung RM, Punt S, Wang Z, Xu C, Williams LJ, Wang Z, Bristow CA, Carugo A, Peoples MD, Li L, Karpinets T, Huang L, Malu S, Creasy C, Leahey SE, Chen J, Bernatchez C, Vashisht Gopal YN, Heffernan TP, Hu J, Wang J, Amaria RN, Garraway LA, Wistuba II, Woodman SE, Roszik J, Davis RE, Davies MA, Heymach JV, Hwu P, Peng W. Functional correlation of increased tumor intrinsic glycolytic activity with resistance to adoptive T cell therapy. Journal for Immunotherapy of Cancer 5, 2017. e-Pub 2017.
90. Lee, WC, Diao, LX, Wang, J, Zhang, JH, Roarty, E, Chow, CW, Fujimoto, J, Behrens, C, Cascone, T, Peng, WY, Kalhor, N, Moran, C, Johnson, FM, William, WN, Swisher, S, Heymach, J, Wistuba, II, Futreal, A, Zhang, JJ. Multiregion gene-expression profiling to reveal heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. J Thorac Oncol 35, 2017. e-Pub 2017.
91. Lee, WC, Diao, LX, Wang, J, Zhang, JH, Roarty, E, Chow, CW, Fujimoto, J, Behrens, C, Cascone, T, Peng, WY, Kalhor, N, Moran, C, Johnson, FM, William, WN, Swisher, S, Heymach, J, Wistuba, II, Futreal, A, Zhang, JJ. Multiregion gene-expression profiling to reveal heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer 35(15), 2017. e-Pub 2017.
92. Reuben, A, Gittelman, R, Zhang, J, Chen, R, Quek, K, Vence, L, Fernandez-Cubelo, I, Behrens, C, Gao, J, Yusko, E, Emerson, R, Benzeno, S, Vignali, M, Tipton, C, Jalali, A, Lee, W, Wu, C, Li, J, Wu, X, Ye, Y, Eterovic, A, Little, L, Gumbs, C, Bernatchez, C, Haymaker, C, Forget, M, Federico, L, Cascone, T, Robins, H, Roarty, E, Rodriguez, J, Parra, E, Wargo, J, Allison, J, Sharma, P, Zhang, J, Lee, J, Sepesi, B, Swisher, S, Gibbons, D, Heymach, J, Futreal, A, Wistuba, I, Zhang, J. Immune, Molecular and T Cell Repertoire Landscape of 235 Resected Non-Small Cell Lung Cancers and Paired Normal Lung Tissues. Journal for Immunotherapy of Cancer 12(11):s1780, 2017. e-Pub 2017.
93. Cascone T, McKenzie JA, Mbofung RM, Punt S, Wang Z, Xu C, Williams LJ, Wang Z, Bristow CA, Carugo A, Peoples MD, Li L, Karpinets T, Huang L, Malu S, Creasy C, Leahey SE, Chen J, Bernatchez C, Vashisht Gopal YN, Heffernan TP, Hu J, Wang J, Amaria RN, Garraway LA, Wistuba II, Woodman SE, Roszik J, Davis RE, Davies MA, Heymach JV, Hwu P, Peng W. Functional correlation of increased tumor intrinsic glycolytic activity with resistance to adoptive T cell therapy 5(2), 2017. e-Pub 2017.
94. Reuben, A, Gittelman, R, Zhang, J, Chen, R, Quek, K, Vence, L, Fernandez-Cubelo, I, Behrens, C, Gao, J, Yusko, E, Emerson, R, Benzeno, S, Vignali, M, Tipton, C, Jalali, A, Lee, W, Wu, C, Li, J, Wu, X, Ye, Y, Eterovic, A, Little, L, Gumbs, C, Bernatchez, C, Haymaker, C, Forget, M, Federico, L, Cascone, T, Robins, H, Roarty, E, Rodriguez, J, Parra, E, Wargo, J, Allison, J, Sharma, P, Zhang, J, Lee, J, Sepesi, B, Swisher, S, Gibbons, D, Heymach, J, Futreal, A, Wistuba, I, Zhang, J. Immune, Molecular and T Cell Repertoire Landscape of 235 Resected Non-Small Cell Lung Cancers and Paired Normal Lung Tissues 12(11):S1780-S1780, 2017. e-Pub 2017.
95. Cascone T, Subbiah V, Hess KR, Subbiah IM, Bhatt T, Owonikoko TK, Heymach JV. Significant systemic and CNS activity of RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with advanced NSCLC with RET fusion. J Clin Oncol, 2016. e-Pub 2016.
96. Peng, WY, Chen, JQ, Liu, CW, Malu, S, Creasy, C, Tetzlaff, M, Xu, CY, McKenzie, J, Zhang, CL, Liang, XX, Williams, L, Deng, WL, Chen, G, Mbofung, R, Lazar, A, Torres-Cabala, C, Cooper, Z, Chen, PL, Tieu, T, Spranger, S, Yu, XX, Bernatchez, C, Forget, MA, Haymaker, C, Amaria, R, McQuade, J, Glitza, I, Cascone, T, Li, HY, Kwong, L, Heffernan, T, Hu, JH, Bassett, R, Bosenberg, M, Woodman, S, Overwijk, W, Lizee, G, Roszik, J, Gajewski, T, Wargo, J, Gershenwald, J, Radvanyi, L, Davies, M, Hwu, P. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Res 76, 2016. e-Pub 2016.
97. Peng, WY, Chen, JQ, Liu, CW, Malu, S, Creasy, C, Tetzlaff, M, Xu, CY, McKenzie, J, Zhang, CL, Liang, XX, Williams, L, Deng, WL, Chen, G, Mbofung, R, Lazar, A, Torres-Cabala, C, Cooper, Z, Chen, PL, Tieu, T, Spranger, S, Yu, XX, Bernatchez, C, Forget, MA, Haymaker, C, Amaria, R, McQuade, J, Glitza, I, Cascone, T, Li, HY, Kwong, L, Heffernan, T, Hu, JH, Bassett, R, Bosenberg, M, Woodman, S, Overwijk, W, Lizee, G, Roszik, J, Gajewski, T, Wargo, J, Gershenwald, J, Radvanyi, L, Davies, M, Hwu, P. Loss of PTEN promotes resistance to T cell-mediated immunotherapy 76(14), 2016. e-Pub 2016.
98. Cascone T, Subbiah, V, Hess, KR, Nelson, S, Nilsson, MB, Subbiah, IM, Ali, SM, Carbone, DP, Salgia, R, Owonikoko, TK, Meric-Bernstam, F, Doebele, RC, Heymach, JV. Significant systemic and CNS activity of RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with advanced NSCLC with RET fusion 34(15), 2016. e-Pub 2016.
99. Cascone T, Hess KR, Piha-Paul S, Hong DS, Roxas M, Subbiah IM, Fu S, Naing A, Janku F, Karp D, Sherman SI, Meric-Bernstam F, Heymach JV, Subbiah V. A phase I study of everolimus (mTOR inhibitor) in combination with vandetanib (multikinase inhibitor of VEGFR, EGFR, and RET) in advanced solid tumors including molecularly matched aberrations. AACR-EORTC Annual Meeting 2015, 2015. e-Pub 2015.
100. Cascone T, Hess KR, Piha-Paul S, Hong DS, Roxas M, Subbiah IM, Fu S, Naing A, Janku F, Karp D, Sherman SI, Meric-Bernstam F, Heymach JV, Subbiah V. A phase I study of everolimus (mTOR inhibitor) in combination with vandetanib (multikinase inhibitor of VEGFR EGFR and RET) in advanced solid tumors including molecularly match aberrations. AACR-EORTC Annual Meeting, 2015. e-Pub 2015.
101. Xia, D, Herynk, M, Xu, L, Cascone, T, Nikolinakos, P, Nilsson, M, Nunez, MI, Saintigny, P, Zhang, L, Girard, L, Gazdar, AF, Minna, J, Wistuba, II, Heymach, JV. Activating Mutant EGFR Upregulates HIF-1 alpha to Promote a Hypoxic Phenotype Independent of Hypoxia in Non-Small Cell Lung Cancer. J Thorac Oncol 10(9):s775, 2015. e-Pub 2015.
102. Wagner KW, Alam H, Dhar SS, Giri U, Li N, Wei Y, Cascone T Giri D, Kim JH, Ye Y, Multani A, Chan CH, Erez B, Saigal B, Lin HK, Wu X, Hung MC, Heymach J, Lee MG. The histone demethylase KDM2A is a new promoter of tumorigenesis, drug target and negative prognostic biomarker for non-small cell lung cancer, 2014. e-Pub 2014.
103. Wagner KW, Alam H, Dhar SS, Giri U, Li N, Wei Y, Cascone T, Giri D, Kim JH, Ye Y, Multani A, Chan CH, Erez B, Saigal B, Lin HK, Wu X, Hung MC, Heymach J, Lee MG. The histone demethylase KDM2A is a new promoter of tumorigenesis, drug target and negative prognostic biomarker for non-small cell lung cancer 74(19), 2014. e-Pub 2014.
104. Nilsson MB, Cascone T, Giri U, Gudikote J, Diao L, Koo A, Lu H, Dogruluk T, Riquelme E, Tran T, Scott K, Wistuba I, Carbone DP, Socinski M, and Heymach JV. KDR (VEGFR-2) copy number gains and mutations are targetable alterations in Non-small cell lung cancer. J Thorac Oncol 8:s350-351, 2013. e-Pub 2013.
105. et al CT. Upregulated stromal EGFR and vascular remodeling in murine NSCLC xenograft models of VEGF-inhibitor resistance. 14th Symposium on Anti-Angiogenic Therapy, 2012. e-Pub 2012.
106. Cascone T. Upregulated stromal EGFR and vascular remodeling in murine NSCLC xenograft models of VEGF-inhibitor resistance, 2012. e-Pub 2012.
107. Saigal B, Herynk MH, Cascone T Nilsson M, Khajavi M, Saintigny P, Heymach JV. Estrogen contributes to bevacizumab resistance in xenograft models of non-small cell lung cancer (NSCLC). Cancer Res 71, 2011. e-Pub 2011.
108. Cascone T, Saigal B, Reynolds DM, Erez B, Jacoby JJ, Nilsson M, Lin HY, Herbst RS, Langley RR, Heymach JV. VEGF inhibitor resistance is associated with stromal EGFR activation and normalized revascularization in an orthotopic model of lung adenocarcinoma. Cancer Res 71, 2011. e-Pub 2011.
109. Morgillo F, Cascone T, Saintigny P, Heymach JV, Ciardiello F. Antitumor activity of MEK inhibitors in human lung cancer cell lines with acquired resistance to different tyrosine kinase inhibitors and with epithelial to mesenchymal transition. J Thorac Oncol 6(6):s926, 2011. e-Pub 2011.
110. Saigal B, Herynk MH, Cascone T, Nilsson M, Khajavi M, Saintigny P, Heymach JV. Estrogen contributes to bevacizumab resistance in xenograft models of non-small cell lung cancer (NSCLC) 71(8), 2011. e-Pub 2011.
111. Cascone T, Saigal B, Reynolds DM, Erez B, Jacoby JJ, Nilsson M, Lin HY, Herbst RS, Langley RR, Heymach JV. VEGF inhibitor resistance is associated with stromal EGFR activation and normalized revascularization in an orthotopic model of lung adenocarcinoma 71(8), 2011. e-Pub 2011.
112. Cascone T, Herynk MH, Xu L, Kadara H, Hanrahan E, Fan YH, Saigal B, Park YY, Lee JS, Langley RR, Jurgensmeier JM, Ryan A, and Heymach JV. Increased HGF is associated with resistance to VEGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). 101st AACR Annual Meeting, 2010. e-Pub 2010.
113. Cascone T, Herynk MH, Xu L, Kadara H, Hanrahan E, Fan YH, Saigal B, Park YY, Lee JS, Langley RR, Jüergensmeier JM, Ryan A, and Heymach JV. Increased HGF is associated with resistance to VEGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC. 101st AACR Annual Meeting, 2010. e-Pub 2010.
114. Herynk M, Cascone T, Xu L, Heymach JV. A role for c-Src in EGFR-induced upregulation of HIF-1α. J Thorac Oncol, 2009. e-Pub 2009.
115. Herynk, MH, Hanrahan E, Lin H, Cascone T, Yan SY, Byers L, Yordy JS, Lee JJ, Heymach T, J V. Secreted cytokine and angiogenic factor (CAF) profiles associated with age and sex in NSCLC. J Thorac Oncol, 2009. e-Pub 2009.
116. Cascone T. A role for stromal EGFR activation in resistance to VEGF blockade in human non-small cell lung cancer (NSCLC) xenograft models”. Cancer Res, 2009. e-Pub 2009.
117. Cascone T, Herynk M, Du D, Oborn C, Kadara, H, Nilsson MB, Lee JS, Langley R, Heymach JV. A role for stromal EGFR activation in resistance to VEGF blockade in human non-small cell lung cancer (NSCLC) xenograft models, 2009. e-Pub 2009.
118. Herynk, MH, Hanrahan E, Lin H, Cascone T, Yan SY, Byers L, Yordy JS, Lee JJ, Heymach T, J. Secreted cytokine and angiogenic factor (CAF) profiles associated with age and sex in NSCLC, 2009. e-Pub 2009.
119. Herynk M, Cascone T, Xu L, Heymach JV. A role for c-Src in EGFR-induced upregulation of HIF-1α, 2009. e-Pub 2009.
120. Cascone T, Herynk M, Du D, Kadara H, Hanrahan E, Nilsson M, Lin HY, Lee, JJ, Park YY, Lee, JS, Heymach, JV. Stromal HGF and VEGFR-1 are associated with acquired resistance to VEGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC)”. J Thorac Oncol 4(9):s412, 2009. e-Pub 2009.
121. Cascone, T, Morgillo, F, Laus, G, Pepe, S, Ciardiello, F. Potentiation of the antitumor activity of bortezomib, a proteasome inhibitor, by the combination with EGFR inhibitors in human cancer cell lines. EJC Supplements 4(12):122, 2006. e-Pub 2006.
122. Cascone T, Forde PM, Peters S, Donington J, Meadows-Shropshire S, Tran P, Lucherini S, Coronado Erdmann C, Sun H, Cascone T. Perioperative vs Neoadjuvant Nivolumab for Resectable NSCLC: Patient-Level Data Analysis of CheckMate 77T vs CheckMate 816. 2024 IASLC World Conference on Lung Cancer.
123. Cascone T, Spicer J, Cascone T, Kar G, Zheng Y, Blando J, Heng Tan T, Cheng M, Mager R, Hamid O, Soo-Hoo Y, Forde P, Weder W, Garcia-Campelo R, Grenga I, Kumar R, McGrath L. Platform study of neoadjuvant durvalumab (D) alone or combined with novel agents in patients (pts) with resectable, early-stage non-small-cell lung cancer (NSCLC): pharmacodynamic correlates and circulating tumor DNA (ctDNA) dynamics in the NeoCOAST stud. ESMO Congress 2022.
124. Cascone T, Chelvanambi M, Deboever N, Nassif E, Damania AV, Chen L, Leung CH, Chin WC, Keung EZ, Witt RG, White MG, Johnson SB, Wong MC, Mishra AK, Lastrapes MJ, Somaiah N, Kadara H, Basu S, Allison JP, Sharma P, McBride KM, Fridman WH, Heymach JV, Sepesi B, Ajami NJ, Roland CL, Wargo JA, Cascone T. Metagenomic sequencing reveals unique gut microbial features associated with tertiary lymphoid structures in response to immune checkpoint blockade in solid cancers. Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting.
125. Cascone T, Awad MM, Spicer J, He J, Lu S, Sepesi B, Tanaka F, Taube JM, Cornelissen R, Havel L, Kuzdzal J, Petruzelka LB, Wu L, Pujol JL, Ito H, Coronado Erdmann C, Sathyanarayana P, Meadows-Shropshire S, Provencio Pulla M. CheckMate 77T: Phase 3 study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIB NSCLC. ESMO Congress 2023.
126. Cascone T, ascone T, Guisier F, Bonanno L, Liberman M, Bylicki O, Insa A, Livi L, Corre R, Egenod T, Bielska A, Yohannes A, Mager R, He Y, Dowson A, McGrath L, Kumar R, Grenga I, Spicer J, Forde P. NeoCOAST-2: Efficacy and Safety of Neoadjuvant Durvalumab (D) + Novel Anticancer Agents + CT and Adjuvant D ± Novel Agents in Resectable NSCLCPL02.07. Oral presentation at the Presidential Symposium. World Conference on Lung Cancer.

Book Chapters

1. Heymach JV, Zurita-Saavedra A, Kopetz S, Cascone T Nilsson MB. Tumor Angiogenesis. In: Cancer Medicine, 2014.
2. Heymach JV, Cascone T. Tumor Microenvironment, Angiogenesis Biology and Targeted Therapy. Lung Cancer. In: Wiley Online Library. 4th, 2014.
3. Cascone T, Gold, KA, Glisson, BS. Small Cell Carcinoma of the Lung. In: The MD Anderson Manual of Medical Oncology. 4th, 2014.